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Hadron therapy is a new treatment technique for cancer. Clinical studies [1] have demon-
strated that hadron therapy is clinically more effective than conventional radiotherapy
as it delivers the dose to the tumour, sparing the healthy tissue. Although this method
reduces the additional dose delivered to the healthy tissues, due to the beam delivery
systems the patients and the personnel are exposed to a secondary dose. Therefore, one
of the main tasks for medical physicists is to make sure that the treatments are delivered
according to the treatment plan.
This thesis is focused on the verification of the secondary dose received by the patient
or the personnel during and after the irradiation sessions at three different facilities:
the Clatterbridge Cancer Centre, the Christie Proton Therapy Centre and OpenMed
at CERN. The ambient dose equivalent calculations were studied using the FLUKA
Monte Carlo code. These calculations investigate whether the shielding methods meet
the existing radiation protection requirements and if the dose delivered to the patients
or staff is kept As Low As Reasonably Achievable (ALARA) [38].
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Chapter 1
Introduction
Nowadays cancer is becoming the leading cause of death world wide. Most cancer cases
are treated with radiation therapy. Frequently, radiation therapy is combined with other
therapies like surgery and chemotherapy [2].
The history of radiation therapy goes back to 1895 when Wilhelm Conrad Rontgen
discovered the X-rays [3]. Ever since, ionizing radiation has been used for diagnosis and
treatment for internal and external radiation therapy and implemented in cancer therapy
programs worldwide. Ionizing radiation can be categorized into: low-LET like photons
and electrons and high-LET like alpha-particles, accelerated ions and low energy-protons
[3].
The principle of radiation therapy is that the radiation deposits the energy as an ab-
sorbed dose, causing damage to cancer cells which will lead eventually to cell death.
Therefore, the main purpose of radiation treatment is to eradicate the cancer while
sparing the healthy tissue surrounding the tumour. Hadron therapy is a good method
because it has the capability to deliver a higher dose to the tumour, while reducing
the dose to the surrounding healthy structures [4]. The depth-dose curve for high-
LET radiation is initially low and after that energy deposition increases rapidly and
immediately it drops to zero. This feature is knows as the Bragg peak [5] The extent of
the relative biological effectiveness increases with increasing LET. The relative biological
effectiveness (RBE) is generally taken as 1.1 [32] but it is increasing with LET up to 100
keV/µm−1 and after is decreasing due to the overkill effect [33]. A detailed description
of the RBE and LET relation is given in section 2.5.3. Figure 1.1 shows the dose rate in
water as a function of depth for charged hadrons (protons and carbon ions), electrons,
X-rays and 60Co (γ rays).
1
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Figure 1.1: Dose rate in arbitrary units, as a function of depth for various particles
as indicated. Taken from [6].
1.1 Research Objectives
Radiation is an important and disputed aspect of modern society. Even if people are
exposed to natural radiation, people are also exposed to artificial sources when we refer
to medical applications. Patients undergoing radiation therapy treatment and people
working in these facilities are exposed to radiation. The radiation can be hazardous
if it is not handled with care. Here is where the radiation protection is applied. The
radiation protection is a field that has the role to protect humans and the environment
from the harmful effects of radiation [7].
This thesis presents different aspects of radiation protection. These aspects are relevant
as the results can affect the safety of personnel, patients and the general public.
This thesis covers only radiation protection for protons, helium ions, carbon ions and
oxygen ions as these ions are used for cancer treatment or research at the facilities
considered.
The objective of this thesis is to estimate the dose of the secondary particles, neutrons
and photons, delivered to the patient or personnel during radiation therapy treatment.
The calculations were made for three facilities: The Clatterbridge Cancer Centre [8],
the Christie Proton Therapy Cancer Centre [9] and the OpenMed facility at CERN [10].
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These results will be used to investigate if the proposed conditions of irradiation satisfy
the radiation protection standards.
1.2 Methods
Monte Carlo simulations have a very important role in radiation therapy [11]. The
simulations are mainly used to verify and to improve the quality of the radiation therapy
treatment. For these studies, the FLUKA [12] Monte Carlo code was used to simulate
the beam line components and the treatment conditions.
FLUKA is a general MC transport and interaction code based on Fortran, which was
developed at CERN and it is mainly used in cosmic ray physics, neutrino physics, accel-
erator design, hadron therapy etc. The code has the capability to import CT scans and
to correct the treatment planning systems but also to study the induced radioactivity
and to simulate the transport of residual radiation. The code is mainly used at CERN
for radiation protection calculations at the LHC but also for other facilities [12].
In the initial stage, an approach to data collection was taken for all three facilities. The
second step was the geometry implementation and the analysis of the distribution of
secondary particles produced. Then, ambient dose equivalent and the residual activity
were calculated, in order to understand the influence on the total dose absorbed by the
patient or personnel. Eventually, this study will lead to create efficient shielding for
patient or staff safety.
The results showed that the production of the secondary neutrons during the irradiation
is dependent on the material located in the proton beam path and also depends on the
design of the beam line, so it is impossible to use a standard configuration. These results
will later be verified by performing measurements during irradiation of various phantoms
and using different types of detectors.
1.3 The Clatterbridge Cancer Centre
Chapter 4 gives an overview of the first (at present) and only proton therapy facility in
UK. The facility is equipped with a cyclotron which provides a 60 MeV proton beam
used to treat different types of ocular tumours [8]. The proton therapy treatment is
delivered using the passive scattering method, therefore the patients will be exposed to
a whole-body irradiation due to the secondary neutrons. As this dose is not added into
the treatment plan, we considered that it is important to calculate the secondary dose
to the patients, as, in time, this dose can lead to development of a secondary cancer.
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This chapter discusses several aspects identified as central for radiation protection. The
first aspect is the proton fluence and the proton dose along the beam line. This study is
very important for the pre-therapeutic studies as it offers information about the quality
of the proton beam distribution into the patient. The next aspect is the neutron fluence
and the neutron dose along the beam line as this dose should be taken into consideration
when the effective dose received by the patient is planned. The third aspect is the
neutron dose equivalent as the radiation protection is based both on a principle of
optimization and individual dose limits. The last aspect was the study of radioactivity
induced in the collimator and in the treatment room as, even if people are benefiting
from this practice, it can also give rise to exposure due to the radioactivity.
1.4 The Christie Proton Therapy Centre
Chapter 5 discusses the radiation protection calculations at the Christie Proton Therapy
Centre. The Christie Proton Therapy Centre is a new facility under construction in
Manchester, UK. The proton therapy facility is designed to have three treatment rooms
and one research room and to deliver proton beams with energy up to 250 MeV [9].
The aim of the work presented in this thesis was to investigate the radiation exposure of
the staff working in the research room and of the patients or public who have access to
the surrounding facilities. The objective is to calculate the ambient dose equivalent for
secondary particles like neutrons and photons and the radioactive nuclides produced by
the irradiation of air and of surrounding structures, including the stainless steel floor.
These studies will help us to calculate the external radiation exposure and also to verify
if the doses are below the legal limits.
1.5 The OpenMed facility
Chapter 6 presents radiation protection aspects for the OpenMed/BioLeir project. This
is a proposed facility at CERN which will provide different types of ion beams to be
used for radiobiological studies, using an old synchrotron used to provide the heavy ions
for the LHC. The LEIR facility is the only facility at CERN which is provided with a
visitor platform. The initial radiation protection studies suggests that for the present
situation, when only Pb ions are accelerated, the dose at the visitor platform level are
below the the CERN regulations for supervised radiation area [10].
Under the new considerations, the FLUKA code was used to calculate the ambient dose
equivalent for different ion beams and with three different beam losses. The aim is
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to determine if LEIR provides appropriate shielding as the research laboratory will be
placed near the accelerator room, and also to establish if the facility needs a roof on top
of the machine.
Chapter 2
Proton Therapy
The idea of proton therapy started with the vision of a man. In 1946, Robert Wilson had
the revolutionary idea that protons can be used clinically, because of the fact that the
Bragg peak of proton beams can be used to place the maximum dose within the tumour,
spearing the healthy tissue [13]. In 1954 the first patient was treated with protons
at Berkeley Radiation Laboratory, but only in 1988 was this approved as radiation
treatment for certain tumours like eye cancer, head and neck cancers, lung cancer, liver
cancer, prostate cancer and spinal cancer.[14] By 2016, because of the increasing interest
in proton therapy, there were 75 proton therapy centres worldwide and more than 154203
patients had been treated with protons [15].
2.1 Basic quantities used in proton therapy
Before describing the physical interactions, it is important to describe some basic quan-
tities used in proton therapy.
2.1.1 Fluence
The fluence Φ is defined as the number of protons, during a given exposure, crossing
the infinitesimal element of area dA normal to x axis. Fluence is a fundamental unit in
dosimetry because it refers to radiation exposures [16].
Φ =
dN
dA
protons
cm2
(2.1)
6
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2.1.2 Stopping power
The parameter used to describe the energy loss is the stopping power [16]. The stopping
power is defined as the average ion energy loss per unit path length.
S = −dE
dx
MeV
cm
(2.2)
The stopping power depends on the type and energy of the particle and on the type of
material it passes through. Starting from this, we can describe the mass stopping power:
S
ρ
= −1
ρ
dE
dx
MeV
g/cm2
(2.3)
where ρ(g/cm2) is the local density of the stopping medium [16].
2.1.3 Physical absorbed dose
The physical absorbed dose is defined as the energy absorbed by matter per unit mass.
The unit used in proton therapy is the Gray. Just to give an idea, a whole body dose of
4 Gy is lethal [16]! Another unit still used in U.S is 1 rad = 10−2 Gy [96].
D =
E
m
J
kg
(2.4)
1 Gy = 1 J/kg
The physical absorbed dose is not a good indicator for biological effects [7]. The radiation
risk is described by the equivalent dose HT . Equivalent dose is expressed in units of
Sievert which implies that biological effects have been taken into account [17].
1 Sv = 1 J/kg as a biological effect [17]
2.1.4 The Ambient Dose Equivalent
The ambient dose equivalent is a quantity used to estimate the effective dose received
by a person during the radiation treatment.
Ambient dose equivalent, H ∗ (d), was defined in ICRU Report 51 [124] as the dose
equivalent that would be produced by an expanded and aligned radiation field at a
depth d in the ICRU sphere. The reference depths are 10 mm for strongly penetrating
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radiation and 0.07 mm for weakly penetrating radiation [18]. The unit used in radiation
therapy is µSv/h [19, 20].
2.1.5 The fundamental equation in radiotherapy
The fundamental equation of radiotherapy is an expression of dose as function of fluence
and stopping power.
If we consider that dN protons pass through an infinitesimal cylinder of area dA and
thickness dx [16]:
D ≡ energy
mass
=
− (dE/dx)× dx× dN
ρ× dA× dx (2.5)
equivalent to
D = Φ
S
ρ
(2.6)
.
Equation 2.6 is mainly used in beam line design or to estimate the dose rate in the
patient [16].
2.2 Interactions of protons with matter
This section describes the interaction of protons with matter for a better understanding
of the dose distribution in the patient. The protons interact with matter through three
main processes: stopping, scattering and nuclear interactions [16].
2.2.1 Stopping
The most important aspect of proton therapy is the fact that beyond the stopping point,
the proton dose is negligible. If the proton beam is monoenergetic, then all the protons
will stop at approximately the same depth. This feature is called Bragg peak [16].
The theory of energy loss was proposed by Bethe in 1930 and Bloch in 1933 [16]. Refer-
ring just to protons and ignoring all the corrections (this is allowed in the radiotherapy
energy range 3-300 MeV), the mass stopping power in a material with atomic number
Z and atomic mass A is given by [3] :
S
ρ
= −1
ρ
dE
dx
= 0.3072
Z
A
1
β2
(
ln
Wm
I
− β2
)
MeV
g/cm2
(2.7)
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where β = v/c is the velocity of the proton and
Wm =
2mec
2β2
1− β2 (2.8)
is the largest possible proton energy loss in a single collision with a free electron. mec
2 =
0.511MeV and is the electron rest energy.
I is the mean excitation energy of the target material. It cannot be calculated very
precisely so it can be found by fitting measured range-energy values (where these are
known) or by interpolation [21].
Knowing the stopping power, we can calculate the range of a proton entering the medium
with kinetic energy E0 until the energy reaches a very low value Efinal
R(Einitial) =
∫ Efinal
E0
(
1
ρ
dE
dx
)−1
dE (2.9)
Another method to describe the range is via the expression
R = d80 (2.10)
where d80 stands for the depth of water at the distal 80% point of the Bragg peak [21].
2.2.2 Multiple Coulomb scattering
A beam of protons travelling into a medium is slowing down and it also scatters, by
interacting with atomic electrons. Due to the countless tiny deflections the process
is called multiple Coulomb scattering (MCS). The MCS angular distribution is nearly
Gaussian for small deflection angles, but not for large angles. In radiotherapy, only the
Gaussian part is considered because it contains about 98% of the protons [22].
2.2.3 Nuclear Interactions
Even though the electromagnetic interactions are dominated, protons also experience
nuclear interactions. Nuclear interactions are divided into two categories [16]:
1) Elastic- when a projectile is scattered off the target nucleus and the total kinetic
energy is conserved;
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2) Non-elastic- when the kinetic energy is not conserved (the projectile or the target
nucleus may be excited into a higher quantum state, or a particle transfer reaction may
occur).
The inelastic interactions are a special type of nonelastic reaction, where the ions are not
conserving the kinetic energy, but they keep their identity before and after the collision,
that means that the final nucleus is the same as the target.
Particles from inelastic and non-elastic nuclear interactions are called secondaries be-
cause the primary particles will be replaced by lighter fragments [16].
In the radiotherapy energy range, the secondaries produced from nonelastic reactions
are protons, neutrons,γ rays, alphas and other secondaries. Most of the final energy will
be found in protons, neutrons and photons as can be seen in figure 2.1:
Figure 2.1: Contribution from secondary particles to the dose depth distribution from
a 150 MeV proton beam in water. Taken from [23].
2.3 Accelerators and beam delivery techniques
In proton therapy the most important aspect is the dose distribution in depth, the energy
has to be at the right value before entering the patient.
Therefore, even though some types of accelerator can produce the proton beam at the
right energy and then deliver it to the patient, it is important to choose the appropriate
technique to send the protons exactly to the tumour. The most common techniques
used are passive scattering and active scanning [24].
The main accelerators used in proton therapy are cyclotrons and synchrotrons [24].
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2.3.1 Cyclotrons
The cyclotrons used in proton therapy can accelerate a proton beam up to energies from
70 MeV (for superficial tumours) up to 250 MeV (for which the range in tissue is 32
cm) [24]. The cyclotron is a compact accelerator, providing a continuous beam of fixed
energy. Even though the beam has a fixed energy, this can be adjusted very quickly
and easily, using a degrader and an appropriate beam design. The most important
components of a cyclotron are:
1) A radio frequency (RF) system - providing the strong electric field to accelerate the
protons;
2) A proton source in the centre of the cyclotron, where the hydrogen gas is ionized and
from which the protons are extracted;
3) A strong magnet to contain the proton beam during acceleration;
4) An extraction system to guide the particles to the gantry;
Cyclotrons used in radiotherapy require a high grade of reliability, low maintenance and
should be easy to operate. The disadvantage of using a cyclotron in proton therapy
is that it does not have the capability to change the energy of the extracted particles,
therefore the energy has to be degraded by adding some material in the beam path and
this will lead to secondary radiation production [24].
2.3.2 Synchrotrons
The synchrotron is a circular accelerator ring. It has the capacity to accelerate the proton
beam until the desired energy is achieved and this allows the beam to be extracted at
any energy. Due to this fact, a synchrotron is a good candidate for active beam delivery.
Compared with a cyclotron, a synchrotron is much bigger, therefore the size reduction
is of major interest.
Other accelerators being investigated for use in proton therapy are: Proton Linacs,
FFAG accelerators, Dielectric Wall Accelerators and Laser-Driven Accelerators. These
new accelerators are good candidates, but they still need to fulfil the safety requirements
in order to prevent a wrong dose or a wrong location into the patient [24]. In conclusion,
the cyclotron and the synchrotron remain the main accelerators used in proton therapy,
and these machines are still improving.
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2.3.3 Beam delivery using passive scattering
Passive scattering is a delivery technique which uses a scattering system to spread the
proton beam and shaping devices to adjust the energy and lateral distribution [24]. A
passive scattering delivery system is showed in figure 2.2.
There are some problems to be solved in order to achieve an appropriate dose deposition.
First, the field aperture for the tumour treatment range (1cm up to 25cm) has to be
covered with a homogeneous beam. For that, the beam has to be broadened using a
single scattering foil (for small fields) or double scattering system (for large fields) [24].
Figure 2.2: Schematic view of a passive scattering system. Taken from [25].
The second problem is covering the entire target. Obviously, the Bragg peak is too sharp
to cover the entire volume so we need to combine proton beams with decreasing energy,
transforming the Bragg peak into a uniform depth-dose region called the spread-out
Bragg Peak (SOBP). This can be obtained using a range (wheel) modulator.
The modulator wheel was first proposed by Robert Wilson: “This can easily be ac-
complished by interposing a rotating wheel of variable thickness, corresponding to the
tumour thickness, between the source and the patient” [26]. A range modulator wheel
has various steps with different thickness, each step corresponding to a peak in the
SOBP, so, by increasing the step thickness, a SOBP can be obtain. The modulator
wheels are made of a low-material Z, like plexiglas or lexan, to limit the scattering.
A third problem is related to the conformation of the dose to the target. Usually, the
treatment field is shaped using a collimator made of brass as shown in figure 2.3. The
distal part of the dose is controlled using a range compensator, made of acrylic or wax,
as shown in figure 2.4. The range compensator has the role of reducing the range of
the protons and it is specific for every patient. The collimator and the compensator are
mounted on the snout on the treatment head, as shown in figure 2.5 . This enables the
air gap between the shaping devices and the patient to be reduced in order to minimize
the effects of scattering in air and thus to reduce the beam penumbra [24].
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Figure 2.3: Collimators. Taken from [27].
Figure 2.4: Range compensators. Taken from [27].
Figure 2.5: The brass aperture at the end of the snout.Taken from [28].
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2.3.4 Beam delivery using active scanning
If the accelerator used for treatment has the capacity to extract the beam at different
energies, the target volume can be scanned in a ”slice by slice” manner as shown in
figure 2.6 [24].
Figure 2.6: Schematical view of the active scanning system. Taken from [25].
The principle of the active scanning is that the scanning starts from the deepest layer
(high energy) and does an x-y scan. After that, the energy is reduced and the next layer
is scanned and so on until all the layers are scanned. There are three different techniques
used in the active scanning method [24]:
1) Discrete spot scanning - A predetermined dose is delivered to a given spot at a given
position, then the beam is switched off and the settings are changed for the next spot,
so the dose will be delivered spot by spot. This method is implemented at PSI [24].
2) Raster scanning - Is similar with the discrete spot scanning, the only difference is
that the beam is not switched off. This method is mainly used for heavy ions and was
implemented at GSI [24].
3) Dynamic spot scanning - The target is continuously scanned [24].
The advantage of active scanning is that is no need for collimators or compensators and
so the beam is interacting less with materials outside the patient, and as a result, the
neutron production will be smaller. The disadvantage of this method is that it is very
sensitive to organ motion [25].
In conclusion, the passive scattering method has several disadvantages compared with
the active scanning method. The protons interact with the scattering material and this
will create unwanted secondary particles. Another problem is that every patient needs
to use a specific collimator and compensator which can be expensive. Despite these,
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the majority of proton therapy centres are using this method to deliver the dose to the
patients. The main reason is that the active scanning method requires a sophisticated
beam control and feedback systems [25].
2.4 Clinical aspects of proton therapy
Clinical use of proton beams has many similarities with the use of conventional x-rays
[16]. The objective of the treatment is to deliver the same amount of dose in every
element of the target. For this, three volumes used as a guide for treatment planning as
shown in figure 2.7:
1) Gross target volume (GTV)- refers to position and extent of the primary tumour;
2) Clinical target volume (CTV)- describes the microscopic extent of the tumour;
3) Planning target volume (PTV)- allows the uncertainties to be added into the planning
and it includes the normal tissue structures in the vicinity of the tumour;
Figure 2.7: Schematical view of the radiotherapy planning volumes. Taken from [29].
As mentioned before, to obtain a homogeneous depth-dose distribution over the entire
volume of the target, it is needed to interpose several Bragg peaks with different incident
proton energies to obtain the spread-out Bragg peak (SOBP). The SOBP will increase
the ability of the proton beam to spare the healthy tissue [24].
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2.4.1 Treatment planning system
The treatment planning system (TPS) is based on clinical information like computed
tomography (CT) and magnetic resonance imaging (MRI). The TPS also provides in-
formation about the treatment delivery system.
The TPS contains all the data to be used in the treatment such as the prescribed range,
the modulation and the imaging information to be used for accurate patient positioning
at the time of the treatment. It is important to take into account the limitations of the
treatment planning system, especially when the dose calculation is involved [16].
2.4.2 Lateral penumbra
Proton therapy has another feature which makes it a good choice in treating cancer.
The protons have a sharp lateral penumbra and this is essential for sparing the healthy
tissue surrounding the tumour. The lateral penumbra depends on a series of factors like
the beam delivery system and the uncertainties of the patient set-up.
For a passive scattering delivery system, the lateral penumbra depends on the position
of the aperture, the range compensator, the air gap between the compensator and the
patient and the penetration depth. In an active scanning system, the lateral penumbra
is broadened by the air gap between the nozzle and the patient.[16]
2.4.3 Field size
In the majority of the cases, proton therapy is used to treat small tumours and this
involves no major problems. Nowadays, proton therapy treatments are expanding for
more diseases such as medulloblastoma (a type of brain tumour) and large sarcomas
(a rare cancer affecting the muscle, bone, nerves, cartilage, tendons, blood vessels and
fatty tissues) which involve much larger target volumes. Even if it is possible to expand
the irradiation field to the largest field size possible, some practical considerations must
be taken into account, for example: the size of the nozzle, the gantry size and the dose
rate [16].
Scattering delivery systems can produce large fields, up to 25 cm in diameter, although
the effective field size is approximately 22 cm. A small snout will allow lighter apertures
and compensators and so the patient can be placed closer, which will make air gap
smaller and therefore the lateral penumbra will be minimised. For the active scanning
delivery system, larger fields will require stronger or longer scanning magnets [16].
Radiation Protection Studies for Radiobiology 17
2.4.4 Dose rate
An efficient beam produces a high dose rate, so that the treatment can be delivered in
a short time. The treatment procedures, is that the patient is first set up by image
guidance and after that, the treatment is delivered assuming that the patient has the
same body configuration as in the last image procedures. This assumption is valid only
for treatment which not take a long period of time, otherwise this aspect can affect the
quality of the treatment, even if patient immobilization devices are used [16].
In proton therapy, there is no need to use a large number of fields, due to its capacity
of sparing the healthy tissue around the target volume. Most of the treatments use
two fields with different combinations, depending on the tumour position. For a regular
treatment, the dose rate is about 1.8-4.0 Gy/min and depends on the target field size
[16].
2.5 Proton biology
2.5.1 DNA Damage
The goal of proton therapy is to eradicate the tumour cells by damaging the DNA [30].
There are two types of lesions which can be induced: single strand break (SSB) and
double strand break (DSB). In the case of SSB, only one strand of the double DNA
helix is damaged, as a result, the DNA repair mechanism has the capacity to rebuild the
damaged strand. In case of DSB, both strands of DNA helix are damaged, which makes
the repair mechanism more difficult, if not impossible and this will cause cell death. In
conclusion, for a better effect, the proton treatment must induce DSBs in the DNA [31].
In cancer therapy it is very important to understand cell survival as a function of dose.
Cell survival curves represent the relationship between the number of cells that have
lost the ability to proliferate and the absorbed dose as shown in figure 2.8. The linear-
quadratic model is the accepted formula to express the survival curves. This model
assumes that the cells can be killed in two ways [30]:
1. Single lethal event
2. Accumulation of sub-lethal events
S(D) = exp(−αD − βD2) (2.11)
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where S- is the fraction of cells surviving a dose
D- the dose
α and β are constants depending on the nature of the cells [30].
Figure 2.8: Cell survival curves. Taken from [31].
2.5.2 Relative biological effectiveness
Relative biological effectiveness (RBE) is a concept introduced to compare the effective-
ness of the protons when compared with other types of radiation [32]. Thus, the RBE
of protons is defined as the ratio between the photon dose and the proton dose used to
achieve the same biological effect as shown in figure 2.8 [32]:
RBE =
Dx−ray
Dp
(2.12)
where, Dx−ray is the photon reference dose and Dp is the proton dose.
Charged particles have different RBE. A high RBE is not an advantage because the
same effect can be achieved with a higher photon dose. In proton therapy, the main
advantage is that the RBE is increased over the Bragg peak area, and this will lead to
increased damage in the tumour and not in the healthy tissue. In practice, the value
used for RBE is 1.1 but this is mainly based on experiments performed at the beginning
of proton therapy [32].
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2.5.3 Linear Energy Transfer
Linear Energy Transfer (LET) is defined as the linear energy transferred to a medium
per unit track length of the particle [32].
L =
dE
dx
(2.13)
On a cellular level, the energy loss can only be approximated, because LET is a macro-
scopic parameter. The LET and the stopping power S described in equation 2.1.5 are
closely associated but the difference is that LET refers to the local energy deposition
and S is describing the total energy lost by the particle. For heavy charged particles,
the LET and S are approximately equal [97]. Some examples of typical LET value are
given in table 2.1 [32]:
Radiation Typical LET values
1.2 MeV 60Co gamma 0.3 keV/µm
250 kVp x rays 2 keV/µm
10 MeV protons 4.7 keV/µm
150 MeV protons 0.5 keV/µm
14 MeV neutrons 12 keV/ keV/µm
Heavy charged particles 100-200 keV/ keV/µm
2.5 MeV alpha particles 166 keV/ keV/µm
2 GeV Fe ions 1000 keV/µm
Table 2.1: Typical LET values [32].
The lethal effect of a charged particle depends on its LET and this affects the RBE [33].
As shown in figure 2.9, the RBE reaches a maximum value at an LET of around 100
keV/µm as a saturation effect. As the LET increases, the RBE increases slowly at the
beginning and more rapidly as the LET increases beyond 10 keV/µm. After 100 keV/µ,
the RBE is decreasing to lower values. This decrease in the high LET region represents
a saturation effect due to ”overkilling” [33, 35].
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Figure 2.9: RBE as function of LET. Taken from [34].
2.6 Proton therapy’s neutron problem
Secondary radiation production is a main concern in proton therapy, because the un-
wanted doses delivered by the secondary radiation can induce a secondary cancer into
the patient. A disadvantage of proton therapy when compared with X-ray therapy is
that the secondary dose received by the patients and staff is higher because of neutron
production and activation [16].
Secondary radiation consists of prompt and residual radiation. Prompt radiation is
produced while the accelerator is working, while residual radiation is produced by ra-
dioactive materials activated during machine operation. Secondary radiation is produced
by the interaction of protons with the beam line components: energy degraders, beam
shaping devices and the beam delivery system. Because of this, shielding is required.
Secondary radiation is produced also in the patient, but these mechanisms are not well
understood [16].
As mentioned earlier, the dose deposited by the secondary radiation in healthy tissue
can have major consequences, affecting cognitive function, the functionality of organs
or even leading to a secondary cancer. The malignancy risk remains even 30 to 40 years
after the initial treatment. The risk also depends on the age of the patient and the type
of tumour [16].
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It has been proved that secondary cancers occur close to the primary cancer treatment
field, where a high dose can induce a sarcoma and even a low dose is associated with a
secondary tumour. This aspect has a huge importance, especially when treating children,
because they are vulnerable to carcinogenic effects.[16]
2.6.1 Secondary neutron dose
When interacting with matter, the primary protons are generating secondary particles
with different ranges: short-ranged (< 1mm like α particles), medium-ranged (secondary
protons) and long-ranged (secondary neutrons). The neutrons are produced when pro-
tons interact with the material in the beam path during the proton therapy treatment,
but also with the patient tissue. Therefore, the patient is exposed to secondary radia-
tion. The dose deposited by secondary particles must be considered, as even for a low
dose, the neutrons can induce secondary cancers due to the fact that they have a high
RBE [16]. The neutron production will depend on the material of the beam delivery
system and on the design of the beam line.
The neutrons, according to [16], can be classified as following:
1. Thermal En ≤ 0.5 eV;
2. Intermediate 0.5 eV < En ≤ 10 keV;
3. Fast 10 keV < En ≤ 20 MeV;
4. Relativistic En > 20 MeV;
5. High-energy neutrons En > 100 MeV;
In proton therapy, it is very important to know the neutron energy spectrum, because
the biological effectiveness of the neutrons depends on their energy. The neutron energy
deposition can be calculated using Monte Carlo simulations. In a typical proton therapy
treatment, the dose is deposited by high energy neutrons (energy above 100 MeV) [16].
2.7 Radiation Protection
Radiation protection is a term used to describe concepts, requirements and operations
applied to protect people against the harmful effects of ionizing radiation. Even though
radiation is used in medical treatments for cancer, the exposure to radiation can lead
to harmful effects such as radiation burns and secondary induced cancer. The major
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purpose of radiation protection is to reduce the radiation risk as it can not be com-
pletely prevented [36]. According to the International Commission of Radiological Pro-
tection (ICRP) [37], the exposure of people to radiation and the radiological impact
on environment should be kept as low as reasonable achievable (ALARA principle) and
should be in accordance with the regulations of national professional bodies and with
the recommendations of the international regulatory authorities. The ICRP stated in
the Recommendation 60 [38] that three basic principles of radiation protection should
be applied:
1. Justification: any exposure of persons to ionizing radiation has to be justified;
2. Limitation: personal doses have to be kept within the legal limits;
3. Optimization: personal and collective doses have to be kept as low as reasonably
achievable (ALARA);
Radiation protection is provided as criteria and a guidance, according to the ICRP,
which can be applied in cases such as nuclear power, radiation therapy and exposure
to natural radiation. The guidance is established by the international organizations
as the International Atomic Energy Agency (IAEA), the Commission of the European
Communities (CEC) and the Nuclear Energy Agency (NEA). In every state, radiation
protection concepts are implemented through national regulations issued by a regulatory
authority. The regulatory authority has the power to license a source, to conduct inspec-
tions and to take enforcement actions. Therefore, the details for the rules of radiation
protection differ throughout the world.[36] In UK, two sets of regulations are used for
radiation protection against ionizing radiation and radiology [39]:
1. The Ionising Radiation Regulations 1999 (SI 1999 No. 3232) (IRR99) [40] ad-
dressed mainly to the safety of workers and general public but includes also the
equipment aspects of patient protection;
2. The Ionising Radiation (Medical Exposure) Regulations 2000 (SI 2000 No. 1059)
IR(ME)R 2000 [41] addressed to the safety of patients;
2.7.1 Radiation protection in clinical/research facilities
Radiotherapy with high energy hadrons is continuously developing and is already used
in many countries as a treatment choice for several types of cancer. Although hadrons
present several advantages over photons, there are several challenges in designing hadron
therapy facilities that can treat a large number of patients efficiently and safely [26].
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When designing a centre, several aspects have to be taken into account: shielding, acti-
vation, the safety system and monitoring. As high energy particles generate unwanted
secondary particles, especially by neutrons, in order to maintain a safe environment two
solutions are applied to avoid radiation hazards [42]:
1. Administrative controls to limit the exposure of the personnel;
2. Shielding to attenuate the radiation level to legal limits imposed by the national
authority;
The evaluation of the radiation protection has to consider the parameters of the ma-
chine, like the beam rate and operation period, but, most importantly, the design that
has to provide protection to patients and staff. This implies verification measurements
of the shielding performance under various operation conditions, periodic reviews of
the machine performance, and radiation measurements [61]. In order to establish the
shielding needed for a hadron therapy facility, analytical techniques are used and verified
with measurements and with Monte Carlo simulations. Recently, two studies [43, 44]
from radiation protection conducted at the Northeast Proton Therapy Centre (NPTC)
Boston, suggested that the Monte Carlo results are in better agreement with measure-
ments than the analytical calculations. The Monte Carlo method has the advantage
that complex geometries and shielding can be modelled in detail. As mentioned, several
aspects have to be fulfilled to provide adequate protection from potential exposure to
radiation. Periodic verifications have to be done to preserve safe working environment
by ensuring that the personnel are not present in areas of high radiation fields. These
safety verifications include also a variety of procedures and automated safety systems,
including proton beam monitoring systems and area monitoring systems for neutrons,
with acoustic and visual alarms if the legal limit is exceeded [42].
Although Monte Carlo methods are used to evaluate the effectiveness of neutron shield-
ing, each hadron therapy facility will have different features that influence its shielding
requirements, such as the accelerator type, beam delivery method and beam energy. In
this section, the radiation protection for three different facilities will be discussed: the
Advanced Proton Therapy Facility (APTRON) [45] under design in Shanghai, as the
extracted beam energy will vary from 70 MeV to 250 MeV and the studies can be com-
pared with the Clatterbridge Cancer Centre and the Christie Proton Therapy Centre
cases evaluated in this thesis, the Italian National Centre for Oncological Hadrontherapy
(CNAO) [46] in Italy as the facility have a cyclotron and a synchrotron and the results
can be compared with both the Christie Proton Therapy Centre and OpenMed facility
evaluated in this thesis, and CERN [47] as the OpenMed project will be based there.
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2.7.1.1 The Advanced Proton Therapy Facility APTRON
The APTRON is a new facility planned to be built in Shanghai. The layout of the facility
includes a 7 MeV Linac injector and a synchrotron capable of accelerating protons from
70 MeV up to 250 MeV. The dose equivalent limit is 2 mSv/year corresponding to 1
µSv/h for staff working full-time. The calculations were carried out for different energies
assuming 100% beam loss and the radiation shielding evaluations were made with the
FLUKA Monte Carlo code. The results showed that shielding wall thickness varies from
1.7 m to 3 m, as shown in fig 2.10, in order to obtain the values of the dose equivalent
below the dose rate limit of 1 µSv/h outside the shielding wall [45].
Figure 2.10: Schematic layout of the APTRON facility. Taken from [45].
2.7.1.2 The Italian National Centre for Oncological Hadrontherapy CNAO
The CNAO facility is equipped with both cyclotron and synchrotron machines. The cy-
clotron is designed to treat tumours with protons up to 250 MeV, while the synchrotron
will accelerate carbon ions up to 400 MeV/u. At this facility, the recommendations of
the ICRP Publication 60 were followed [25]. The dose objectives are 2-3 mSv/year for
radiation workers and 0.25 mSv/year for non-exposed workers and the public. The limit
for the activity of the air released into the environment is < 1 Bq/g. The radiation
protection evaluation at this facility was done with the FLUKA Monte Carlo code. The
effective dose (Sv/carbon ion) behind the shielding walls was evaluated. The dose was
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calculated for a beam energy of 400 MeV/u and for wall thickness between 1 meter and
6 meters. The main contributors to the radioactivity released in air have an activation
lower that 1 Bq/g for a 60 MeV beam being on for 24 hours continuously. Based on
these calculations, the air activity concentration at CNAO is expected to be < 1 Bq/g
[46].
2.7.1.3 CERN
CERN is an international research facility with many accelerator complexes able to
accelerate particles up to 7 TeV. The radiation protection policy at CERN is based on
ALARA principle and it complies with the regulations of the host states (Switzerland and
France) and with the recommendations of competent international bodies [47]. All these
recommendations are incorporated into CERN’s radiation safety code [48]. According
to this code, the areas inside CERN are classified by the effective dose received by a
person during a stay in the area under normal working and operational conditions [48]:
1. Non-designated Areas;
2. Supervised Radiation Areas;
3. Controlled Radiation Areas;
The radiological classification and limits are shown in figure 2.11 taken from [49].
Figure 2.11: Classification of Radiation Areas at CERN taken from[49].
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The CERN dose limits comply with IRR99 dose limits as shown in figure 2.12 taken from
[40]. As the majority of the workers at CERN are exposed to ionizing radiation, the dose
received is monitored with personal dosimeters. For personnel working in Controlled
Radiation Areas, where the dose rate is above 50 µSv/h, an additional operational
dosimeter is mandatory [47]. Every facility at CERN has a combination of features that
strongly influence the shielding requirements, therefore different methods are applied
in order to keep the dose below legal limits. The Radiation Protection group uses the
FLUKA Monte Carlo code to conduct studies for all facilities to evaluate the dose and
the radioactivity induced in different elements like air, water and soil.
Figure 2.12: IRR99 dose limits taken from [40].
2.7.2 Monte Carlo codes used in radiation protection
Several studies [43, 44] have suggested that Monte Carlo calculations are in a good
agreement with the relevant radiation measurements. Monte Carlo is a useful method
to study new strategies in diagnosis and therapy, to evaluate new techniques and to plan
the therapy treatment with accuracy [50]. The advantages of the Monte Carlo tools are
that the complex geometries can be modelled in detail, a wide variety of physics processes
can be implemented over an extended energy range, and the user has the possibility to
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visualize the experimental set-up with a simple user interface. In the area of medical
physics applications, several Monte Carlo codes are used, the most used are: GEANT4
[51], FLUKA [52] and MCNP [53]. A detailed overview of these codes is given in chapter
3.
2.7.2.1 GEANT4 Monte Carlo Code
GEANT4 [51] is a powerful tool which was originally developed for Particle Physics
detectors and has been extended for use in diagnosis, radiotherapy and dosimetry. The
GEANT4 simulation toolkit is a C++ library in which the user can write a program to
define the problem. This code has the capability to model the experimental set-up in
detail: beam line, radioactive sources and the patient anatomy [51].
The GEANT4 Electromagnetic Physics manages electrons, leptons, photons and muon
interactions and provides implementations of ionization, Bremsstrahlung, multiple scat-
tering, photoelectric absorption and Compton scattering. The GEANT4 Hadronic
Physics offers both parametrization-driven models and theory-driven models and treat-
ment of low energy neutron transport [51].
These features are relevant and offer advanced functionality for the GEANT4 simula-
tion tool-kit which is used in various domains of medical physics: radiotherapy [54],
brachytherapy [55, 56], hadron therapy [57], dosimetric studies at cellular level [58] and
radiodiagnostic as PET and SPECT [59].
2.7.2.2 FLUKA Monte Carlo Code
FLUKA [52] is a general Monte Carlo radiation transport code that has the ability
to track nearly all particles over an extended energy range. The FLUKA code was
mainly developed for applications in detectors and accelerators, but new improvements
have made FLUKA a standard tool to investigate beam-machine interactions, radiation
damage and radiation protection issues. The FLUKA code is the principal tool used for
radiation protection calculations for all accelerator complexes at CERN [52].
The FLUKA code is suitable for applications to hadron therapy as it provides reliable
physical models for the description of the transport and the interaction of all components
of the expected radiation field. Its physical database is based on laterally integrated
depth-dose profiles, lateral dose distribution at different depths, secondary fragment
yields and fragment energy spectra at different depths. Future developments of the
FLUKA code will include the improvement of physical models for oxygen and helium
ions as they are used in clinical studies for a possible use in hadron therapy [52].
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2.7.2.3 MNCP
MCNP [53] is a general Monte Carlo particle transport code that can be used for single
or coupled neutron/photon/electron transport. It has been widely used in nuclear power
designs and it is clearly an old program as the documentation still refers to the input
file as a “deck” of “cards” [79].
MCNP has been successfully used to calculate Bremsstrahlung spectra from medical
linear accelerators, for modelling dose distribution, and to evaluate the dosimetric prop-
erties of a radioactive source. The code is used also to simulate radiation transport for
neutron capture therapy treatment planning as the code has detailed physics models
for neutron, photon and electron interactions. The MCNP code has the capability to
record and to transport individual particles which is an advantage for treatment planning
calculations [61, 62].
2.8 Activation processes in Accelerators
Activation induced in accelerator components represents one of the main radiation haz-
ards of high-energy accelerators. Beam line components such as targets, collimators,
magnets and beam dumps become highly radioactive as a result of direct interactions of
the primary beam or indirect interactions of the secondary particles [68].
The hadronic secondary are produced along the beam line through spallation processes.
The secondaries will activate the accelerator components as they pass through and the
activity induced will be found even after the accelerator has shut down. Hence, high
energy accelerators have a high radiological impact on the environment due to both
prompt and residual radiation [63]. Neutrons and photons dominate the radiation field.
The personnel will be exposed when handling, transporting, maintaining and storing
the machine components. This exposure can exceed the permitted limits, therefore it is
important to predict correctly the unstable radionuclides produced as they are unstable
and will undergo radioactive decay [64].
The induced radioactivity will depend on the beam loss, the material composition and
the production cross section of the isotope concerned. The radioactivity will depend
also on the isotope half-life and the time that the accelerator was operational.[63, 64]
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2.9 Radioactivity
Radioactivity or radioactive decay occurs when a high energy particle interacts with
a nucleus which may emit secondary particles such as neutrons or protons or electro-
magnetic radiation as gamma radiation. That means that many nuclei are produced
in excited states and de-excite by emitting neutrons, charged particles or fragments
through a so called evaporation process. They may also de-excite by emitting gamma-
rays. If the secondary particles have enough energy, they can cause further activation
through spallation processes or they can be captured by nearby nuclei. The new nuclei
produced have a high probability of being a radioactive isotope. Therefore, the radioac-
tivity induced in an accelerator will strongly depend on the primary beam losses, on the
primary beam energy, on the beam line material and on the secondaries produced. The
derived SI unit for radioactivity is Becquerel (Bq) which is equal to one disintegration
per second [63].
From the point of view of radiation protection, the most important radioactive isotopes
are the long-lived ones as they can cause serious problems during maintenance and
during decommissioning of an accelerator facility, and also because of the activation of
the beam line components, concrete or air can induce radiation exposure to patients and
workers [63, 64] The most common radioisotopes produced in an accelerator structure
and their half life (T1/2) are listed in table 2.2 [65–68].
As well as the machine components which are fixed, the air surrounding the accelerator
and the cooling water will become activated also due to the secondary radiation. The
radioactivity induced in air and water represents an additional hazard that needs to be
studied in order to avoid a possible exposure of personnel and public if the radioactivity
is released in the environment where the accepted levels may be low.
The most dangerous isotopes that are found in irradiated air and water are short-lived
positron emitters that are produced in oxygen and nitrogen. The production of 7Be
and 3He by spallation reactions in air and water and 41Ar produced by thermal neutron
capture in the natural argon in air, has to be evaluated in every radiation protection
study for a high energy particle accelerator facility [69]. These isotopes are responsible
for the dose received by humans.
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Material Radionuclide T1/2
Aluminium 3H 12.33 y
7Be 53.22 d
22Na 2.6 y
Iron as above plus
44mSc 2.44 d
46Sc 83.8 d
47Sc 3.35 d
48Sc 1.82 d
48V 15.97 d
51Cr 27.7 d
52Mn 5.59 d
54Mn 312.1 d
55Fe 2.74 y
59Sc 44.5 d
56Co 77.2 d
57Co 271.7 d
58Co 70.9 d
St. Steel as above plus
59Ni 75 y
60Co 5.27 y
Copper as above plus
63Ni 100 y
65Zn 243.7 d
Table 2.2: The most abundant radionuclides with half-life longer than 2 days present
in accelerator structures after irradiation [65–68].
2.10 Hadron therapy
Nowadays, there are many facilities using protons, but there are some institutes who
have developed therapy units for treatment of cancer with 12C [70].
When compared with protons, there are some advantages and disadvantages to using
12C ions. Due to the fact that 12C is heavier, the 12C ions are less scattered than 1H
in lateral direction, and the Bragg peak is narrower. Therefore, the 12C ions can be
used to irradiate tumours closer to organs, like the spinal cord or the optic nerve. These
advantages make the 12C suitable for deep seated tumours. Carbon ions have also a high
RBE, which means that they are biologically more effective. Despite these, there are also
some disadvantages. When the carbon ions interact with matter, they are fragmented
due to collisions with the atomic nuclei. These interactions lead to an attenuation of
the primary beam intensity and to production of secondary fragments (neutrons and
lighter ions) which will have larger penetration ranges and will lead to a dose tail at
the distal side of the Bragg peak. There is also a positive aspect, as the fragmentation
process produces also lighter carbon isotopes which can be used for a positron emission
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tomography (PET) analysis. Another disadvantage is that due to their larger charge,
the energy loss is higher than that of protons, hence, the beam energy needs to achieve
the same penetration depth is higher, which means that larger accelerators are needed.
This is why synchrotrons are used in the existing facilities [71].
In the last decades, there has been larger interest to use 16O 4He and 20Ne ions. While
4He ions are similar to protons regarding their biological effectiveness, for 16O the LET
is high which makes it a good candidate for the irradiation of hypoxic tumours [70].
Chapter 3
Monte Carlo Simulations
3.1 Introduction
This chapter describes the Monte Carlo (MC) methods used to simulate interactions
and transport of neutrons, protons and other particles in different media depending on
their nature: photons undergo Compton scattering, photoelectric absorption and pair
production, electrons undergo Bremsstrahlung, hadrons undergo elastic and inelastic
scattering with atomic nuclei, charged particles suffer Coulomb scattering and energy
loss [72]. This technique was developed in 1940 for the initial development of nuclear
weapons and the name represents a reference to the famous casino in Monaco [73]. MC
techniques are widely used in many areas of research as they can approximate solutions
to quantitative problems through statistical sampling [74]. Monte Carlo simulations use
random samples from a given distribution to evaluate or to approximate solutions for
complex models or physical problems [72].
The difference between MC methods and analytical or numerical approaches is that the
MC uses a random number generator and a set of probability distributions to sample
parameter values for calculating a possible solution to the problem for a single “case”
or “event”. When multiple “cases” or “events” are simulated, average values can be
obtained. Therefore the result is associated with a standard deviation that express the
uncertainty. This type of uncertainty is not present when using analytical or numerical
methods, but the analytical method can still present uncertainties due to the errors
introduced in the model as it is difficult to analyse complex problems [75].
The MC method has the advantage that it can provide the solution of a problem, cre-
ating a virtual experiment based on an input. Provided with the correct information
through the input (particles, energy, geometry, boundaries, material composition etc.),
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the Monte Carlo method can simulate and track primary particles and also secondary
particles created in the interactions.[72][74] This method is widely used in physics and
more recently in applied fields such as medical physics to create different experimental
conditions which are difficult to build experimentally [75].
The use of the MC method in modelling the particle transport through matter was
described by Rogers and Bielajew [76]: “The Monte Carlo technique for the simulation
of the transport of electrons and photons though bulk media consists of using knowledge
of the probability distributions governing the individual interactions of electrons and
photons in materials to simulate the random trajectories of individual particles. One
keep of physical quantities of interest for a large number of histories to provide the
required information about the average quantities.” This description applies also for
neutrons, protons and other types of particles.
In medical physics, the Monte Carlo method started to be used with the rise of the accel-
erators used for radiotherapy. Monte Carlo methods were developed for dose prediction
and dosimetry. There are several reviews on the use of MC in medical physics [76–78].
These studies suggest that the MC results are in a better agreement with measurements
than analytical methods as complex geometries can be implemented and the sources and
the shielding can be modelled in detail. In radiotherapy, Monte Carlo is widely used to
simulate the patient’s, treatment conditions and also for dose calculation [77, 77]in order
to ensure adherence to the safety regulations. Another advantage of using the Monte
Carlo method in medical physics is that the user can manipulate the physics modelling
through a number of transport parameters. The user can determine the cut-off energies
or to choose which particles can be discarded. This will increase the efficiency of Monte
Carlo calculations and the calculation speed will be increased [74].
For a dose calculation, the track of each individual ionizing particle through the volume
is simulated. Along the path through matter, the particle will undergo different types
of interactions: Compton scattering, Coulomb scattering or nuclear interaction. The
MC method will use a random number generator and probability distribution for these
interactions to sample the distance l to the next interaction for a particle at a given
position and with a velocity v in a certain direction. The particle will be propagated
with velocity v over the distance l to the interaction point and the MC code will choose
a type of interaction that will occur. As the dose is defined as the amount of energy
deposited per unit mass (J/Kg=Gy) [96], the code will calculate the energy loss: the
energy of the projected particle minus the energy of the outgoing ones. If the dose
is calculated in a specific volume, the code adds the contribution from all interactions
occurring in this volume and divides this by the mass in the volume [75].
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However, the results of any MC simulations could be affected by the physical models,
by the accuracy of the information provided in the input or by the number of histories.
Hence, the results should always be compared with experimental measurements where
possible, if not, more that one simulation code should be used to compare (benchmark)
the results [72].
There are three Monte Carlo codes that are widely used in radiotherapy : FLUKA [52],
GEANT4 [51] and MCNP [53] [75].
For the work presented in this thesis, the FLUKA Monte Carlo Code was used. The
reason of choosing FLUKA as the simulation code is that it is a free code, widely used
in radiation protection evaluation and it provides an easy-to-use tool that helps the user
to edit the geometry, to execute the code, and to visualize the results more easily. An
additional reason for choosing this code is that several studies showed that the FLUKA
results agree more with the experimental measurements than GEANT4 and MCNPX
and it has a high simulation efficiency [42, 82]. During the research period various
versions of the code were used, but all the results refer to FLUKA, 2011.2c-4 the latest
version of the code [79, 80].
For the Clatterbridge Cancer Centre project, the results obtained with FLUKA were
compared with MCNPX results obtained by Annelie Laidler. The MCNPX results were
calculated using the same geometry for the beam line as in FLUKA.
For the Christie Hospital Centre project, the neutron dose equivalent values calculated
with FLUKA were compared with MCNPX results obtained by Alex Flynn.
3.2 MCNPX
MCNPX [60] is a general-purpose Monte Carlo transport code that has the capability to
track all particles at all energies. MCNPX is an extension of MCNP and it was developed
at Los Alamos National Laboratory in 1994. The name MCNP stands for Monte Carlo
N-Particle Transport Code. The Monte Carlo code is widely used for neutron studies,
in the design of accelerator spallation targets, in investigations for accelerator isotope
production and nuclear waste transmutation, medical physics, the design of shielding in
accelerator facilities and research into accelerator-driven energy sources [61].
The MCNPX code can be used in several transport modes: neutron only, photon only,
electron only, combined neutron/photon transport, neutron/photon/electron or elec-
tron/photon. The neutron energy regime is from 10−11 MeV to 20 MeV and the photon
and electron energy regimes are from 1 keV to 1000 MeV [81].
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One of the advantages when using MCNPX is that the code does not require any pro-
gramming by the user. The user needs to provide an ASCII input file with the informa-
tion about the geometry, the sources (energy and angular spectra), the tallies (energy
deposition or track length) and the variance reduction techniques. The final results are
provided as ASCII output files. A graphical user interface is available to generate in-
put files and to visualize the output data. It has also the capability to allow the user
to specify a wide range of source conditions without modifying the code. Independent
probability distributions may be specified for the source variables of energy, time, posi-
tion and direction and other parameters as starting cell or surface. The user can also
request various tallies related to particle, current, particle flux and energy deposition.
All tallies are normalized per starting particle [82].
MCNPX uses for nuclear data continuous-energy nuclear and atomic data libraries. The
primary sources of nuclear data are taken from the Evaluated Nuclear Data File (ENDF),
the Evaluated Nuclear Data Library (ENDL) and the Activation Library (ACTL). Nu-
clear data tables are available for neutron interactions, neutron-induced photons, photon
interactions, neutron dosimetry or activation and thermal particle scattering [82].
For the energy range used in radiotherapy, the MCNPX code employs the tabulated data
library for nucleon-induced reactions for projectile energies less than 150 MeV. The data
file used for neutrons is LA150N and LA150H for protons. For this energy range, the
MCNPX code uses the Bertini model as default, and Coulomb diffusion and elastic and
inelastic scatterings are also considered. The cut-off energy is usually set to 100 keV for
electrons, photons and protons and with no threshold for neutrons [82].
MCNPX code is a general-purpose, continuous-energy, generalized-geometry, time-dependent
and with an energy deposition mesh-tally that makes it a good candidate for many ap-
plications in medical physics, including the dose calculations in partial body irradiation.
There are several advantages in using the MCNPX code: the explicit modelling of com-
plicated geometries, the extensive cross section library for low energy reactions (< 20
MeV), the capability to calculate the statistical uncertainties, the mesh tally that can
provide spatial distributions independently of the problem model, the complete library
of neutron cross section and the fact that the code is not requiring programming skills.
The disadvantages are that the code is not a free source and the calculations can take
time to obtain a suitable statistic for small regions. Another disadvantage is that the
input format can be tricky to implement for a new user [81].
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3.3 GEANT4
GEANT (GEometry ANd Tracking) [83] is a simulation toolkit that was originally de-
veloped for high-energy physics in the C++ language. Due to the latest development
in particle, nuclear and radiation physics, new demands for accurate and comprehensive
simulations had risen. As a response to these demands, the GEANT simulation code
was developed. The code can be widely used in various studies, from basic phenomena
to full-scale detector simulations for the LHC [83].
The GEANT4 code includes built-in steering routines and command interpreters which
operate at the setup, run, event, particle transport, visualization and analysis levels.
The software is based on a set of physics models that can handle particle interactions
across a wide energy range. The software contains components like event generation,
reconstruction and analysis that represent what are used for real data simulations. The
code is very flexible and allows the user to customize and implement only the physics that
is suitable for the study. The geometry of the experimental setup can be implemented
through a large number of components with different shapes and materials [84].
The global structure of the simulation toolkit includes different categories that are ca-
pable of managing the runs, the events and the tracks. This allows the simulation of
the event kinematics and the primary and secondary tracks. In GEANT4, the tracking
does not depend on the particle type or the specific physics processes. The particle is
moved step by step, which allows the optimization of the execution performance. The
GEANT4 Geometry module allows the user to model the geometry structure and to
propagate particles through it. GEANT4 Electromagnetic Physics can manage many
particle interactions like: leptons, photons, muon, hadrons and ions. It also provides im-
plementations regarding ionization, Bremsstrahlung, multiple scattering, photoelectric
absorption, Compton scattering and synchrotron radiation. Low energy processes down
to 250 eV for photons, electrons, hadrons and ions are also implemented. The GEANT4
Hadronic Physics offers various theory-driven models and also it treats low-energy neu-
tron transport [84].
All these features make GEANT4 a powerful and versatile toolkit that can be used in
medical applications, especially in the simulations of secondary particles in proton and
ion therapy. GATE and TOPAS are two simulation platforms based on the GEANT4
toolkit that are used for radiation therapy and dosimetry applications The code can
simulate a wide range of physics processes based on theory or experimental data. The
GEANT4 toolkit is continuously improved and developed for many applications from
medical physics to high-energy astrophysics or accelerator design [83]. Like any other
Monte Carlo code, the GEANT4 simulation toolkit has advantages and disadvantages.
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The mainly advantage is that the user can add extra features to extend the program
to other areas that for which the code was originally intended. It is a free source code,
very flexible and with the capability of implementing or modifying any physics processes
without changing other parts of the software. Another important advantage is that the
user can implement physics models according to the needs. But this advantage can be
also a disadvantage as due to the variety of available hadronic models, the user has to
combine them adequately to describe the initial interaction stage. Another disadvantage
is the fact that the user needs to have C++ programming skills to be able to use the
GEANT4 toolkit [85].
3.4 The FLUKA code
FLUKA is a general MC transport and interaction code developed for high-energy
physics with fully integrated physical models which allows the users to add their own
scoring and sources files [79, 86]. The code is written in Fortran and it is used for calcula-
tions of particle transport and interactions with matter. It can be applied in cosmic ray
physics, neutrino physics, accelerator physics, particle physics, shielding design, dosime-
try, space radiation, hadron therapy, neutronics etc. FLUKA was developed in 1962
by Johannes Ranft to be used for hadronic beams at CERN. Between 1970 and 1987,
the code was used mainly for shielding calculations. The name of FLUKA was given
later, when the code was used in calorimetry, and it stands for FLUktuierende Kaskade
(Fluctuating Cascade). In 2003, a collaboration between CERN and INFN started with
the aim of developing the code in areas of interest such as dosimetry, medical physics
and radiobiology [86]. Presently, FLUKA has the capability to simulate with high ac-
curacy the interaction and propagation in matter for more than 60 different particles
with energies from 1 keV to TeV: neutrinos, muons with different energy, hadrons with
energies up to 20 TeV and all the corresponding antiparticles, neutrons down to thermal
energy and heavy ions. The program can also transport polarised and optical photons
[87, 88].
This code has the capability to import CT scans and to correct the Treatment Planning
System (TPS) and also to study induced radioactivity, decay and transport of residual
radiation. Particle cascades produced by prompt radiation and residual radiation can
be simulated in parallel in order to distinguish them. This allows the user to score
the quantities independently. With FLUKA the user can calculate the prompt dose
or the residual dose equivalent using a user-defined irradiation and cooling profile. All
quantities can be presented in 1D, 2D or 3D plots [89]. FLUKA also has the capability
to deal with low-energy neutron components of the cascade and this feature is very
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important as the user can include electronics and other sensitive detector parts. In
addition, radiation damage calculations and shielding design can be applied not only for
proton accelerators but also for electron accelerators of any energy, photon factories or
any type of radiation source, be it artificial or natural [90].
When compared with other MC codes, FLUKA has the highest simulation efficiency
and is much faster. The simulation efficiencies studies showed that FLUKA is a factor
of 4 faster than the MCNPX and a factor of 14 faster that the GEANT4 [42]. For
a simulation with 106 primary histories (number of samples) there is no need for a
supercomputer, as the running time is around 4 or 5 hours.
Despite of all these features, FLUKA has also disadvantages due to the code weaknesses:
the physics is not exact (all codes are based on different physics models and some models
are better than others), the code configuration cannot be modified, artefacts can occur
due to the imperfect algorithms and data uncertainty. Problems may also be due to
the user: material composition not always well known, geometries that may not be
reproduced exactly and may be other area of user ignorance [79].
The FLUKA code is available without charge, together with the graphical interface
FLAIR, that is available for output processing and plotting. As the role of the FLUKA
code is to provide the best physics available, all the relevant physical models are im-
plemented as packages. For particle therapy, FLUKA uses different physical models
such as EMF (ElectroMagnetic FLUKA) which contains the electromagnetic physics
which accounts for energy loss, straggling and multiple Coulomb scattering of charged
particles. For ion projectile energies from 5 GeV/n down to 100 MeV/n, a relativistic
Quantum Molecular Dynamics (rQMD) model is employed for nucleus-nucleus inter-
actions [90, 91] For lower energies, a model based on the Boltzmann master equation
(BME) theory is used to describe hadronic interactions. De-excitation of the excited
fragments is processed by the FLUKA evaporation/fission/fragmentation module. The
hadron-nucleus interactions are implemented in the PEANUT (Pre-Equilibrium Ap-
proach to Nuclear Thermalization) framework [90, 91]. For momenta below 3-5 GeV/c,
the PEANUT package includes a very detailed Generalised Intra-Nuclear Cascade and
a pre-equilibrium stage, while for high energies the multiple collision mechanism is in-
cluded. Both modules are followed by equilibrium processes: evaporation, fission and
gamma de-excitation. For neutrons with energy lower than 20 MeV, the FLUKA code
uses its own neutron cross section library with more than 250 different materials used for
simulations in physics, dosimetry and accelerator design [93]. All models described above
have been benchmarked for both therapeutic proton and carbon ion beams [91, 92].
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3.5 Physics settings for simulations
The results presented in the next chapters have been calculated using the latest version
of the code. The physics settings were optimised to obtain accurate simulations. For
all three inputs used for the Clatterbridge Cancer Centre, the Christie Proton Therapy
Centre and the OpenMed facility, the configuration recommended for precision simu-
lation was chosen. The default set of parameters was activated using the DEFAULTS
card, with the PRECISIOn option, used for precision simulations. This option includes
by default [37]:
Option
EMF model
Rayleigh scattering and inelstic form factor corrections to Compton profiles
Detailed photoelectric edge treatment and fluorescence energies
Low energy neutron transport down to termal energies
Fully analogue, the physical reality is simulated giving no importance to the geometry areas
Particle transport treshold set to 100 keV, except neutrons
Multiple scattering threshold at minimum allowed energy, for primary and secondary
Delta ray production with threshold of 100 keV
Heavy particle bremsstrahlung activated with explicit photon production above 300 keV
Muon photonuclear interactions activated with explicit generation of secondarie
Heavy fragment transport activated
Table 3.1: The default options includes in the FLUKA Monte Carlo simulations [37].
Additionally, the Evaporation and Heavy fragments options were activated for ac-
curate description of the nuclear processes and to obtain the residual nuclei production
[92, 93].
In order to calculate the fluence and the dose equivalent additional options were added
to the PRECISIOn option:
• USRBIN - the USRBIN is used to score the distribution of different quantities
(fluence, dose) independent of the geometry. Using this option, the user can select
the structure of the mesh (spatial, cartesian or by region). Together with the
fluence and the dose equivalent, USRBIN allows the user to score the activity or
the energy deposited. In the inputs used for all simulations presented here, the
USRBIN was selected to score the ambient dose equivalent.
• AUXSCORE - this option is always used together with URSBIN option as it
allows the association of scoring detectors of certain estimator types with dose
equivalent conversion factors, and filter particles or isotope ranges in accordance
with the needs of the user. The reason of activating the AUXSCORE card is
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that the user can provide the energy dependent coefficients for the conversion of
fluence to ambient dose equivalent for neutrons, protons, charged pions, muons,
photons and electrons. In the cases presented in the next chapter, the Ambient
dose equivalent from ICRP74 [94] and Pelliccioni data (AMB74) [95] was chosen
for proton, neutrons and photons [93].
For activation studies several other cards were activated:
• RESNUCLE - this option scores the residual nuclei produced on a region basis, for
each object separately. The user can choose the type of products to be scored. For
all three studies presented in this thesis, all residual nuclei were scored (spallation
products and low-energy neutron ) [93].
• RADDECAY was inserted for simulation of radioactive decays and sets the trans-
port conditions like the cooling time. For the results presented here, five cooling
times were used: after irradiation, 1 hour, 1 month, 3 months and 1 year. The
RADDECAY option offers the possibility to perform on-line time evolution of de-
cay radiation according to the user-defined irradiation profile and one or more
decay times. The RADDECAY card requires the DCYSCORES card.
• DCYSCORES associates the detectors, the estimator type and the user decay
time for radioactive product scoring. In the evaluations presented in this thesis,
due to the fact that five cooling times were used, to each cooling time an index
is assigned, following the order in which it has been added into the input. This
index is then used in the DCYSCORE to assign that particular cooling time to
the scoring detectors. DCYTIMES defines the decay times after irradiation for
the radioactive product scoring. Multiple cards for this option can be added, up
to a maximum of 20 decay times.
• IRRPROFI was used to define the irradiation profiles, such as the beam intensity
and the irradiation time [93].
A complete list of the options used for simulations is given in the Appendix.
Together with FLUKA, the FLAIR software was used. FLAIR [93] stands for FLUKA
Advanced InteR-face and is an advanced friendly interface for FLUKA to facilitate the
editing of FLUKA input files, execution of the code, geometry debugging, checking of the
output files and visualization of the final results. It is based on Python and Tkinter. It
was developed by Vasilis Vlachoudis for FLUKA users to work on an intermediate level
and to verify every option using the FLUKA manual. FLAIR provides also a geometry
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editor which helps the user to visualize the geometry in 2D, to debug bodies and regions
in a graphical way, to obtain a 3D rendering of the geometry and to display complex
geometries [93].
In conclusion, all these capabilities make FLUKA a very powerful code which can be
used in various domains according to the needs of the user.
Chapter 4
Neutron background studies at
the Clatterbridge Cancer Centre
4.1 Introduction
The Clatterbridge Cancer Centre is the first and, at present, the only proton therapy
facility in the UK. In 1984 a 62 MeV cyclotron was installed for treatments of radio-
resistant tumours with fast neutrons [98]. The machine was called the Douglas Cyclotron
after a benefactor who helped fund the equipment [99]. Because the 62 MeV proton beam
is suitable for proton therapy, having a maximum clinical range of 31 mm in water, a
room equipped with an ocular beam line was built. A schematic view of the ocular beam
line can be seen in figure 4.1 [98]. The Clatterbridge cyclotron delivers the beam using
the passive scattering method. The first patients were treated in 1989 and, since then,
the facility has treated more that 2000 patients [98].
This studies were conducted at the request of Dr. Andrzej Kacperek to investigate
neutron production during proton therapy treatment and to establish how this secondary
dose influences the final dose received by the patient. The activation of the beam line
components and the air activation in the treatment room were also considered, as these
could lead to an additional exposure to radiation of the patient and the personnel.
Finally, this study will help us to look for methods to reduce the neutron dosage and
thus the risk of induced secondary cancers.
42
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Figure 4.1: Schematic of the Clatterbridge beam line, courtesy of Dr Andrzej
Kacperek.
4.2 The simulations
Monte Carlo simulations of the ocular beam-line were carried out using the FLUKA
and MCNPX codes to compare the dosimetric accuracy for proton and neutron doses.
The MCNPX simulations were done by Annelie Laidler and the results obtained are
presented in [102]. For the activation studies and residual dose rates, only the FLUKA
code was used.
For all simulations presented in this chapter, the latest version of the FLUKA Monte
Carlo code was used: FLUKA 2011.2c.2. The pre-selected default PRECISIO was se-
lected for all simulations. This options uses transport cuts of 100 keV for electrons,
positrons and photons. The neutrons are transported down to thermal energies [93].
The electromagnetic physics was described by the EMF package, while the Boltzmann
master equation (BME) theory was used to describe the hadronic interactions.[88] The
hadron-nucleus nuclear interactions were treated by the PEANUT (PreEquilibrium-
Approach-to-Nuclear-Thermalization) [88].
For activation studies, the IRRPROFI option was used to define the irradiation profile,
while RESNUCLE and DCYSCORE options were used to estimate the activity of the
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residual nuclei produced in the brass collimator and in air. The ambient dose equivalent
rate was calculated using the USRBIN, DCYSCORE and AUXSCORE options. The
results are given in µSv/s [93].
The results of the FLUKA simulations were calculated for proton beam energies between
55 MeV and 60 MeV. The maximum energy value was set at 60 MeV because this is the
maximum energy provided by the Douglas Cyclotron.
For the MCNPX code, the proton transport physics of this code included energy strag-
gling, multiple Coulomb scattering, elastic and inelastic scattering and nonelastic nuclear
reactions. The neutrons were transported down to thermal energies. The results for the
MCNPX code were calculated only for a proton beam with an energy of 60 MeV. More
information about the MCNPX simulations can be found in [102].
For both codes, a simple geometry was used for simulations. A box (8 × 8 × 15.9
cm) was used as a water phantom (from 184.1 cm to 199 cm) in order to simulate the
patient tissue. The water phantom was placed at 7 cm from the collimator which gave
acceptable lateral beam spread.
The passive scattering components of the beam line were simulated, as shown in figure
4.2. The nozzle is 7 cm long and has a 34 mm internal diameter. A brass collimator
was used to collimate the beam. The collimator aperture size was set at 1 cm. The
total distance between the source and the patient is 180 cm. The simulations were
performed using an un-modulated beam. The beam intensity is 3.12× 1010 particles/s.
Each simulation was made with a set of five runs, giving a total of 5× 106 protons which
is enough for acceptable statistical error [89, 92].
Figure 4.2: The Clatterbridge passive scattering system as simulated in FLUKA,
showing the pre-collimator, 1st scattering foil, kapton window, modulator, 2nd collima-
tor, monitor chamber, beam nozzle, patient collimator and water phantom (compare
with figure 4.1).
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4.3 Results
4.3.1 Bragg peak
For the first set of simulations, the Bragg peak was calculated in order to be compared
with the experimental value. A 60 MeV proton beam was used to hit the water phantom.
A pure mono-energetic proton beam was considered, as this represents the ideal case.
The FLUKA and the MCNPX codes were used for this Monte Carlo simulations and
the results obtained were compared with the experimental values taken from [98]. The
FLUKA simulation result showed that for a 60 MeV proton beam, the Bragg peak occurs
at 3 cm depth in the water phantom as shown in figure 4.3. This is in agreement with
the experimental results obtained in [98].
The FLUKA result was verified using the MCNPX code as presented in [102] and this
is also shown in figure 4.3. The geometry used is the same as that used in FLUKA.
The result shows clearly that the Bragg peak can be seen at approximately 3 cm depth.
In conclusion, the peak location for 60 MeV protons showed no significantly differences
between the FLUKA and the MCNPX codes when compared with the experimental
measurements. This demonstrates that the FLUKA and the MCNPX Monte Carlo
codes can reliable calculate the proton dose distribution.
The same simulations are conducted with the FLUKA code for proton beams with
energies from 55 MeV up to 59 MeV, in order to study the depth-dose distribution as
function of beam energy. The results showed that the depth-dose distribution increases
in range when the proton beam energy is increased, as expected. The results are shown
in figure 4.4.
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Figure 4.3: Depth-dose distribution in water phantom for a 60 MeV proton beam
obtained with experimental results [98], FLUKA and MCNPX [102] along z axis.
Figure 4.4: Depth-dose curves for a proton beam between 55 MeV and 60 MeV
obtained in the water phantom (position between 184.1 cm and 199 cm in the FLUKA
geometry) along the z axis.
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4.3.2 Proton fluence and proton dose along the beam line
The next set of simulations was done to study the proton fluence distribution along the
beam line.
The fluence is given in particles per cm2 and it describes the density of particle tracks.
The FLUKA results were normalized by the beam intensity which is 3.12 × 1010 parti-
cles/s so the fluences are presented for one second of operation.
This study is a very important aspect of pre-therapeutic studies as it offers informa-
tion about the influence of the beam line components (scattering foils, range shifters,
collimators) on the quality of the proton beam, which can be modified due to energy
loss, multiple scattering and nuclear interactions. This can cause a non-uniform proton
fluence distribution, hence a non-uniform dose distribution to the patient [100, 101].
The geometry used to study the proton fluence and dose is the same as used previously.
The results are presented only for proton beams of 55 MeV and 60 MeV as these represent
the extreme values used for treatment. The proton travels from left to right and at the
furthest right it enters the phantom. For 60 MeV both FLUKA and MCNPX codes
were used to determine the proton fluence.
Figure 4.5 shows the results for a proton beam with an energy of 55 MeV. The highest
values was found in the modulating devices, 109 protons/cm2, and in the brass collimator
106 protons/cm2.
Figure 4.5: Proton fluence for 55 MeV along the beam line calculated in FLUKA.
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Figure 4.6 shows the result obtained with FLUKA for a 60 MeV proton beam. The
FLUKA result was compared with the MCNPX result showed in figure 4.7 for the same
beam energy.
Figure 4.6: Proton fluence for 60 MeV along the beam line calculated in FLUKA.
Figure 4.7: Proton fluence for 60 MeV along the beam line calculated in MCNPX.
Taken from [102].
The results obtained with both Monte Carlo codes agreed very well. Most secondaries
are obtained in the modulating devices and at the brass collimators. For a 60 MeV
proton beam, the maximum fluence obtained is 109 protons/cm2 into the modulating
devices and 106 protons/cm2 into the patient brass collimator. The MCNPX results are
expressed in protons per cm2 per source particle and need to be multiplied by the beam
intensity 3.12 × 1010 particles/s, mentioned above, in making a comparison.
Next, the proton dose coming out from the beam line was calculated for a 55 MeV and
a 60 MeV proton beam, using the same characteristics as previously. The results are
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presented in figure 4.8 and figure 4.9. For this set of simulations, only the FLUKA
Monte Carlo code was used.
Figure 4.8: Proton dose for 55 MeV along the beam line calculated in FLUKA.
Figure 4.9: Proton dose for 60 MeV along the beam line calculated in FLUKA.
The results showed no important differences between a 55 MeV and a 60 MeV proton
beam. The maximum proton dose coming out from the beam line is reasonably low 1×
104 GeV/g. In conclusion, the beam line components does not alter the quality of the
proton beam and most of the protons will reach the water phantom.
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4.3.3 Neutron fluence and neutron secondary dose along the beam line
The dose delivered to the healthy tissue by the secondaries it is a possible way of con-
cern. These calculations are important to see if the patient is exposed to a whole body
irradiation.
The production of secondary neutrons will depend on the geometry and the materials
of the proton beam delivery system. For this work the configuration used was the one
described in figure 4.2. A brass collimator was used to conform the beam to the tumour
volume [100].
For the simulation of the neutron fluence and neutron dose along the beam line, a 60
MeV proton beam was used. For neutron fluence along the beam line, the FLUKA
results were compared with the MCNPX results.
The neutron fluence obtained with the FLUKA code is shown in figure 4.10. As for
proton fluence, the neutron fluence was found to be higher in the modulating devices
and the brass collimator, approximately 105 neutrons/cm2.
The values obtained with the MCNPX code are showed in figure 4.11. The highest dose
was obtained in the beam nozzle and in the brass collimator. The MCNPX results show
a good agreement with the results obtained with the FLUKA code.
Figure 4.10: Neutron fluence for 60 MeV in the beam line calculated with FLUKA.
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Figure 4.11: Neutron fluence for 60 MeV in the beam line calculated with MCNPX.
Taken from [102].
Figure 4.12: Neutron dose for 60 MeV in the beam line calculated with FLUKA.
The next task was to calculate the neutron dose. This was calculated with the FLUKA
code using the same input and parameters as for proton dose.
The results showed that most of the neutrons dose is produced around the brass compo-
nents of the beam line as shown in figure 4.12. The maximum neutron dose was found
to be 1 GeV/g for each set of operation.
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4.3.4 Neutron dose equivalent
The Clatterbridge Cancer Centre uses a passive scattering system to deliver the proton
beam, therefore the patient will be exposed to a whole-body neutron dose.
The aim of this study is to estimate this potential exposure of the patient to secondary
radiation. For this, the neutron ambient dose equivalent has been simulated. A model
where the eye diameter was 24 mm and the tumour was in the centre of the eye where
the Bragg peak occurs (approximately 3 cm depth) was considered [100].
In FLUKA, the dose equivalent is given in pSv/primary. As the maximum beam intensity
delivered by the cyclotron is 3.12×1010 p/s, the normalization factor: 10−6×3.12×1010
was used in order to obtain the results in µ Sv/s. This normalization factor is valid
when the maximum beam intensity is used. If the proton treatments use a lower beam
intensity, the normalization factor just scales. A proton beams of 55 MeV and 60
MeV were used for comparison. For radiation protection purposes, the AMB74 option
(Ambient dose equivalent from ICRP74 [94] and Pelliccioni data [95]) was used. For 60
MeV, the result obtained with FLUKA was verified with MCNPX.
The neutron dose equivalent inside and outside the irradiation field was calculated. The
FLUKA Monte Carlo results determined that the neutron dose equivalent goes to greater
depths in the target as the proton energy is increased (energy range is 55 MeV-60 MeV).
For a 55 MeV proton beam, the neutron dose equivalent in the target volume was found
to be 50 µSv/s. Outside the target volume, the dose is between 10 µSv/s and 1 µSv/s
and it goes up to 13 centimetres depth from in the water phantom as shown in figure
4.13.
When the energy was increased to 60 MeV, the neutron dose equivalent deposited in
the target volume was found to be 70 µ Sv/s. After the target volume, the neutron
dose equivalent is decreasing from 20 µ Sv/s to 1 µ Sv/s as shown in figure 4.14. This
estimation is made for a neutron dose deposited in tissue not irradiated with primary
particles. The MCNPX results showed a significant agreement with FLUKA results as
shown in figure 4.15. The highest neutron dose was found around the Bragg peak, at 3
cm depth in the water phantom, around 4×10−6 µ Sv/h/primary and after, the neutron
dose is decreasing down to 2.9×10−8 µ Sv/h/primary. This corresponds to 35 µ Sv/s
and 25 µ Sv/s for a beam intensity of 3.12×1010 p/s.
These results are relevant only for eye treatment (low energy) and cannot be used to
evaluate the radiation exposure of other tissues, as the ambient dose equivalent is sen-
sitive to energy. These results do not take into account the neutron production in the
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Figure 4.13: Neutron dose equivalent for 55 MeV in the water phantom calculated
with FLUKA.
Figure 4.14: Neutron dose equivalent for 60 MeV in the water phantom calculated
with FLUKA.
patient. Therefore, a full study will be needed to understand the mechanism of the sec-
ondary neutron generation inside the body and to estimate the complications induced
by these internal neutrons [100].
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Figure 4.15: Neutron dose equivalent for 60 MeV in the water phantom calculated
with MCNPX. Taken from [102].
In conclusion, for both Monte Carlo codes, the simulations showed that neutron dose
equivalent is increasing, from 50 µ Sv/s to 70 µ Sv/s, as the incident beam energy is
increased from 55 to 60 MeV and that the maximum value of the neutron equivalent
dose is close to the position of the Bragg peak and, after this, it is decreasing gradually.
These values indicate that the secondary neutron dose equivalent is small and not a
problem for clinical treatments.
Unfortunately, the results obtained with the Monte Carlo methods can not be compared
with any experimental measurements from Clatterbridge as no such type of measure-
ments were conducted as this facility. Therefore, in order to benchmark the results
presented in this section, the values of the neutron dose equivalent were compared with
the experimental values measured at a similar facility, CCB IFJ PAN in Krakow [103].
The neutron dose equivalent was measured for a 60 MeV proton beam using a neutron
rem meter in two locations: the patient chair and on the floor near the patient chair.
The results obtained were 0.82 µ Sv/s at the patient chair and 0.25 µ Sv/s on the floor.
These values are considered low and not hazardous for the patients as they are small
compared with the limits set by The Ionising Radiation Regulations 1999 [40], where
the maximum allowed dose for a person exposed to ionising radiations from the medical
reasons is 5 mSv in any period of 5 consecutive calendar years [40].
4.3.5 Study of radioactivity induced in a patient-specific collimator
and in the treatment room
Activity induced in beam line components by particle nuclear interactions is an impor-
tant aspect of radiation protection. Elements such as collimators become radioactive as
a result of induced activation. Induced radioactivity is produced due to direct nuclear
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interactions of the incident beam or indirect interactions of secondary particles with the
nuclei of the materials of the beam line components, in which unstable isotopes are pro-
duced. The activation causes ambient dose rates inside the facility room, and also in the
accelerator components. Therefore, these components must be treated as radioactive
waste [69]. This radiation induced in the accelerator components and air depends on
several factors: particle type, energy, beam intensity and the materials irradiated.
The Clatterbridge Cancer Centre is delivering a beam using the passive scattering sys-
tem. The passive scattering system requires several components in the beam line in
order to provide uniform coverage of the target. The proton beam will interact with
these components and will produce high-energy neutrons. The dominant source of the
neutron dose is the final collimator located close to the patient [25].
The purpose of this study is to evaluate the radioactivity of a patient-specific brass
collimator, calculating the residual dose rates and the activities of the radionuclides
generated during the irradiation since this device is used consecutively during the treat-
ment and this aspect is very important for patients’ and therapists’ safety[104–106]. The
collimators are usually made of brass. Brass is an alloy of copper and zinc. The brass
density can vary from 8.4 to 8.7 g/cm3.
The collimator aperture has the shape of the target and has the role to shape the proton
beam and to block the protons from the outer region of the tumour volume. This device
is manufactured for every patient which means that the therapists have to change it after
every treatment session and, therefore, the radioactivity studies are very important as
these devices can become radioactive due to exposure to the proton beam [104–106].
The simulations were performed for a 60 MeV proton beam impinging a brass collimator,
modelled as a brass block with a density of 8.52 g/cm3 with a central aperture. The
block dimensions are 8 × 8 × 2.5 cm. The radius of the aperture is 1 cm. The irradiation
profile was set for 1 minute irradiation time per day, for 3 days with one day off between
the sessions. The beam intensity was set for 3.12 × 1010 protons per second as this is the
intensity used for treatments. The radionuclides and the ambient dose equivalent rate
were calculated for five decay times: at the end of irradiation, after 1 hour, 1 month, 3
months and 1 year.
The IRRPROFI option was used to define the irradiation profile, while RESNUCLE and
DCYSCORE options were used to estimate the activity of the residual nuclei produced
in the brass collimator. The ambient dose equivalent rate was calculated using the
USRBIN, DCYSCORE and AUXSCORE options. The results are given in µSv/hour
[93].
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Radionuclide T 1/2 Activity (Bq) Activity limit (Bq) [40]
206Bi 6 d 1.9 × 103 105
205Bi 15.31 d 1.4 × 103 106
203Pb 51 h 4.9 × 103 106
203Bi 11.76 h 8.2 × 103 106
202Bi 1.72 h 3.2 × 103 106
201Tl 72.91 h 4.7 × 102 106
201Pb 9.33 h 1.1 × 103 106
201Bi 108 m 5.6 × 102 106
200Tl 26 h 1.0 × 102 106
200Pb 21 h 1.3 × 102 106
70Ga 21.14 m 1.3 × 102 106
69Zn 56.4 m 4.3 × 102 106
68Ga 67.71 m 6.4 × 103 105
67Cu 61.83 h 3.6 × 102 106
67Ga 3.261 d 6.5 × 103 106
66Ga 9.49 h 1.2 × 104 105
65Ni 2.51 h 1.5 × 102 106
65Zn 244.26 d 4.3 × 102 106
65Ga 15.2 m 5.8 × 103 105
64Cu 12.7 h 4.7 × 104 106
63Zn 38.47 h 6.7 × 104 105
62Zn 9.18 h 2.2 × 104 106
61Co 1.65 h 7.5 × 102 106
61Cu 3.33 h 7.4 × 104 106
60Cu 23.7 m 1.1 × 104 105
58Co 70.86 d 7.3 × 102 106
57Co 271.7 d 1.5 × 102 106
57Ni 35.6 h 5.2 × 102 106
56Mn 2.57 h 93.7 105
Table 4.1: The most abundant radionuclides in the collimator after irradiation for a
60 MeV proton beam together with the limits allowed by IRR99 [40].
The activities of the most abundant radionuclides produced in the collimator immedi-
ately after irradiation, are listed in the table 4.1 together with the limits allowed by
IRR99 [40].
After one hour of cooling time, the most abundant radionuclides can still be identified
in the collimator as shown in table 4.2. After 1 month of cooling time, radionuclides
with a longer half-lives are shown in table 4.3. The others fall essentially to 0. The
radionuclides present after 1 month of decay are still present after 3 months of decay
of cooling time, apart from 206Bi, 67Ga which have already disappeared as shown in
table 4.4. The activity of radionuclides with half-lives longer than 1 year is insignificant,
therefore the results will not be discussed.
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Radionuclide T 1/2 Activity (Bq) Activity limits (Bq) [40]
206Bi 6 d 1.9 × 103 105
205Bi 15.31 d 1.4 × 103 106
203Pb 51 h 4 × 102 106
203Bi 11.76 h 7.7 × 103 106
202Bi 1.72 h 2.1 × 103 106
201Tl 72.91 h 4.6 × 102 106
201Pb 9.33 h 1.1 × 103 106
201Bi 108 m 3.9 × 102 106
200Tl 26 h 1.0 × 102 106
200Pb 21 h 1.2 × 102 106
70Ga 21.14 m 8.0 106
69Zn 56.4 m 3.1 × 102 106
68Ga 67.71 m 3.5 × 103 105
67Cu 61.83 h 3.6 × 102 106
67Ga 3.261 d 6.4 × 103 106
66Ga 9.49 h 1.1 × 104 105
65Ni 2.51 h 1.1 × 102 106
65Zn 244.26 d 4.3 × 102 106
65Ga 15.2 m 3.8 × 102 105
64Cu 12.7 h 4.4 × 104 106
63Zn 38.47 h 2.2 × 104 105
62Zn 9.18 h 2.1 × 104 106
61Co 1.65 h 4.9 × 102 106
61Cu 3.33 h 6.0 × 104 106
60Cu 23.7 m 1.9 × 103 105
58Co 70.86 d 7.2 × 102 106
57Co 271.7 d 1.5 × 102 106
57Ni 35.6 h 5.1 × 102 106
56Mn 2.57 h 72 105
Table 4.2: The most abundant radionuclides in the collimator after 1 hour of cooling
time for a 60 MeV proton beam together with the limits allowed by IRR99 [40].
Radionuclide T 1/2 Activity (Bq) Activity limit (Bq) [40]
206Bi 6 d 70.3 105
205Bi 15.31 d 3.6 × 102 106
65Zn 244.26 d 3.9 × 102 106
58Co 70.86 d 6.0 × 102 106
57Co 271.7 d 1.4 × 102 106
Table 4.3: The most abundant radionuclides in the collimator after 1 month of
cooling time for a 60 MeV proton beam together with the limits allowed by IRR99 [40].
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Radionuclide T 1/2 Activity (Bq) Activity limit (Bq) [40]
205Bi 15.31 d 23.9 105
65Zn 244.26 d 3.3 × 102 106
58Co 70.86 d 3.3 × 102 106
57Co 271.7 d 1.2 × 102 106
Table 4.4: The most abundant radionuclides in the collimator after 3 months of
cooling time for a 60 MeV proton beam.
The results obtained for this study, showed that the short-lived isotopes like 202Bi
(T1/2= 1.72 h),
201Bi (T1/2= 108 m),
70Ga (T1/2=21.14 m),
69Zn (T1/2=56.4 m),
68Ga
(T1/2=67.71 m) will not be accumulated in the collimator.
Other isotopes, with longer half-lives like 66Ga, 64Cu, 63Zn, 62Zn, 61Cu and 58Co will
not decay completely and the activity will still be high after 1 hour of cooling time
even though they are in the IRR99 limits by a factor of 10, the ALARA principle
suggests that the exposure after one hour from irradiation should be minimized. Special
attentions should be given to 64Cu as the activity is high and this radioisotope is a
gamma emitter causing radiation exposure and 58Co is another dangerous radioisotope
as it is considered carcinogenic [105, 106]. Direct contact should be avoided or tools
should be used to handle the contaminated collimator. When compared with the activity
limits recommended in IRR99 [40], the activity of certain isotopes like 68Ga, 66Ga, 64Cu,
63Zn, 62Zn, 61Cu and 60Cu will have a significant activity but the values do not exceed
the limits allowed by IRR99 [40] immediately after irradiation. Even after one hour of
cooling, the activity of 66Ga and 63Zn is still only by a factor of 10 lower than the legal
limits [40].
These findings strongly suggest that the patient collimator should be regarded as non-
radioactive but the personnel should wait one hour before handling the brass collimator
to minimize the external exposure.
In order to verify these results obtained with FLUKA Monte Carlo code, a collimator
was measured using a Sodium Iodide counter. Unfortunately, no results were obtained
as the collimator was older than a year. However this confirmed the absence of the
long-lived isotopes as predicted.
After simulating the radioactivity induced in the patient collimator, another important
aspect is to calculate the radioactivity induced in the air of the treatment room. The
treatment room geometry was estimated from observation as no engineering plans were
available. The dimensions considered were 6 x 4 x 3 m. The wall thickness is 3 m. These
dimensions are general dimensions for a proton therapy treatment room [107]. During
the proton treatment, the protons interact with matter, producing fast neutrons. The
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fast neutrons will interact with the atoms from the air, producing short-lived radionu-
clides like 15O, 13N, 11C [107]. After multiple collisions, the fast neutrons will slow
down to thermal energies. The thermal neutrons will be captured by the 40Ar from the
air and radioactive 41Ar will be produced. 41Ar is a beta and gamma emitter and it
represents the major contributor of the air activation [107, 108]. As these radioisotopes
and 7Be (produced by protons on nitrogen) are the principal ones responsible for the
dose induced to public and staff [107], only the activity for these radioisotopes will be
presented in the tables below.
Radionuclide T 1/2 Activity (Bq) Activity limit (Bq) [40]
41Ar 109.61 m 6.1 × 102 109
15O 122.24 s 5.4 × 101 109
13N 9.96 min 4.7 × 105 109
11C 20.33 min 5.4 × 105 106
7Be 53.28 d 9.3 × 103 107
Table 4.5: The most abundant radionuclides in air after irradiation with a 60 MeV
proton beam.
After irradiation, the simulations showed that 15O, 13N, 11C and 7Be are the primary
activation products of air as shown in table 4.5. For 11C, the activity was found to
be 10 times lower than the limit suggested in IRR99 [40]. For 41Ar, 15O and 13N the
activity in air is significantly lower than the IRR99 limit [40], while 7Be has the lowest
activity. These findings suggest that immediately after irradiation, the induced activity
in air is lower than the legal limits and the treatment room can be freely accessed as
the personnel will not be exposed to a radiological risk.
After 1 hour from the irradiation, the 15O has entirely disappeared as shown in table
4.6, while the activity of 41Ar, 13N, 11C and 7Be will be 10 times lower.
Radionuclide T 1/2 Activity (Bq) Activity limit (Bq) [40]
41Ar 109.61 m 4.1 × 102 109
13N 9.96 min 7.2 × 103 109
11C 20.33 min 7.0 × 104 106
7Be 53.28 d 9.3 × 103 107
Table 4.6: The most abundant radionuclides in the air after 1 hour of cooling time
with a 60 MeV proton beam.
The medium half-live radiosotope 7Be will still be present in the air after 1 month, 3
months and 1 year of cooling time, but the activity will be significantly lower.
The results demonstrate that immediately after irradiation, the activity induced in air
is lower than the IRR99 limits [40], therefore, the radioactivity induced in air does not
represent a radiological risk to the personnel. Nevertheless, for these results the air was
Radiation Protection Studies for Radiobiology 60
considered stationary. If the ventilation system is operational during treatment sessions
this could release radioactivity into the environment. This will require expanded study.
In order to calculate the induced residual dose rate produced by the interactions of
protons with the beam line components, air and concrete in the treatment room, further
simulations were made using the same irradiation profile as above: 1 minute irradiation
time per day, for 3 days with one day off between the irradiation sessions. The dose rate
was calculated for 4 cooling times (after irradiation, 1 hour, 1 month and 3 months).
As mentioned before, treatment room dimensions were just assumed as no engineering
plans were available. The ambient dose equivalent was calculated along the central axis
X-Z of the collimator. The results are given in µSv/hour.
Figure 4.16: Residual dose in beam line, concrete and air after irradiation for a 60
MeV proton beam.
The results showed that the residual dose in the treatment room, immediately after
irradiation is of the order of several µ Sv/h, especially near the beam line and it decreases
gradually, to 1 µ Sv/h near the exit, as shown in figure 4.16. Due to the fact that no
door was added in the simulations, the dose outside the treatment room is around 1 µ
Sv/h in the doorway and it decreases behind the shielding wall. After 1 hour the dose
near the beam line is still of order of 5 µ Sv/h, but near the exit, the value is lower than
1 µ Sv/h, as shown in figure 4.17. Behind the shielding wall, the dose decreases down
to 10−5 µ Sv/h. After 1 month, the value of the dose is 0.5 µ Sv/h in the beam line
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Figure 4.17: Residual dose in beam line, concrete and air after 1 hour of cooling time
for a 60 MeV proton beam.
Figure 4.18: Residual dose in beam line, concrete and air after 1 month of cooling
time for a 60 MeV proton beam.
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Figure 4.19: Residual dose in beam line, concrete and air after 3 month of cooling
time for a 60 MeV proton beam.
area and around 10−5 µ Sv/h outside the treatment room as shown in figure 4.18. After
3 months from irradiation, the residual dose equivalent decreases down to 0.05 µ Sv/h
near the beam line and it decreases down to 10−6 µ Sv/h at the exit point as shown in
figure 4.19.
The aim of these calculations was to provide residual dose values for radiation safety
purposes for patients and personnel. They should help to ensure compliance with the
UK regulations and to reduce the potential harmful of external radiation exposure. As
the UK regulations are [40]: 20 mSv in a calendar year for employees aged 18 years
or over, including members of the public and 1 mSv in a calendar year for any other
person, including members of the public and employees under 18 who cannot be classed
as trainees and pregnant employees, the results obtained show that the ambient dose
equivalent values are well within these limitations.
4.4 Conclusion
Proton therapy is a complicated technique and the accuracy of the treatment depends
on several factors arising from the physical and biological properties of the processes
involved and practical constraints of the treatment itself.
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An important aspect in proton therapy is the secondary radiation produced during the
treatment. The secondary particles, like neutrons, can induce an unplanned dose in the
healthy tissue and that could lead to a secondary cancer.
For this work, Monte Carlo simulations were performed, using beam line parameters of
the Clatterbridge Cancer Centre, to calculate the proton depth-dose distribution, the
proton and neutron fluence in the beam line, the neutron dose equivalent in the water
phantom, the radioactivity of beam line components and the activation of air.
The proton depth-dose distribution was calculated for a proton beam with an energy
between 55 MeV and 60 MeV. For 55 MeV, the Bragg peak was found to be at approxi-
mately 2.2 cm depth in the water phantom and the depth-dose distribution is increasing
with energy. At 60 MeV, the Bragg peak occurs at 3 cm depth. The experimental calcu-
lations were verified with the FLUKA and the MCNPX Monte Carlo codes. The results
showed a good agreement between the codes and the measurements and give confidence
in the simulations.
The proton fluence and the proton dose were calculated in order to establish if the
quality of the proton beam is altered along the beam line. The result showed that most
of the particles are produced in the modulating devices and in the brass collimator, but
even in these components, the proton fluence was found to be low. The proton dose was
found to be 105 GeV/g which is very small. The proton dose was calculated with both
FLUKA and MCNPX codes and the results show a good agreement. These findings
suggest that the beam line components will not influence the quality of the proton beam
delivered to the patient.
The neutron fluence and the neutron dose were also calculated. The results showed that
the highest fluence of 105 neutrons/cm2 is found in the brass collimator. The neutron
dose was found to be low, even around the brass components it was found to be 1 GeV/g.
The contribution of the neutrons to the dose was also determined. For a 60 MeV proton
beam, the maximum neutron dose equivalent ranged between 50 µ Sv/s and 70 µ Sv/s
in the target volume and between 20 µ Sv/s and 1 µ Sv/s outside the target. These
findings indicate that for the Clatterbridge Cancer Centre, the secondary neutron dose
equivalent induced to the patient is low below the UK limitations [40].
Certain FLUKA simulations have been verified with MCNPX code and the results
showed a substantial agreement, but it will be important to validate the simulations
with experimental data. As no experimental measurement of the neutron dose equiva-
lent are available for the Clatterbridge Cancer Centre facility, the results obtained were
compared with the experimental measurements conducted at a similar facility at CCB
IFJ PAN in Krakow [103]. The measurements at this facility were done for a 60 MeV
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proton beam using a neutron rem meter. The results obtained were 2.89 mSv/h at the
patient chair and 0.9 mSv/h on the floor. These findings suggest that the secondary
dose received by the patient do not exceed the legal limits suggested in the IRR99 [40].
The activity induced in the patient collimator and in the air inside the treatment room
was investigated. The activation results indicate that the short-lived isotopes like 202Bi,
201Pb, 70Ga and 69Zn will not be accumulated in the patient specific collimator but other
isotopes like 66Ga, 64Cu, 63Zn, 61Cu, 58Co will produce radioactivity even after an hour
of cooling time. The activity of these isotopes does not exceed the limits recommended
in the IRR90 [40] but even after one hour of cooling time, the activity of 66Ga and 63Zn
will be only by a factor of 10 lower that the legal limits [40]. These results suggest that
the collimator is non-radioactive but the personnel should treat it with care to minimize
the radiological risk. Nevertheless, the total activity and the dose rate will strongly
dependent on the irradiation profile: beam intensity, duration of each irradiation session
and the time between the irradiation sessions.
The activation of the air inside the treatment room was also calculated for the same
irradiation profile. The results showed that the medium and long-lived isotopes like
15O, 13N, 11C and 7Be are the primary activation products of air. The activity of 11C
was found to be 10 times lower than the limits set by the IRR99 [40]. These results
suggest that immediately after irradiation, the induced activity in air is within the
legal limits and the access in the treatment room should not be limited. In practice,
the induced activity will depend on the duration of each run and of the number of air
changes in the treatment room.
The residual dose equivalent was also calculated in the treatment room for four cooling
times. The results showed that even after immediately irradiation the residual dose
equivalent was found to be only 10 µSv/h. This value suggest that the residual dose
equivalent is low and it complies with the UK regulations [40].
Chapter 5
Radiation protection studies for
the Christie Proton Therapy
Centre
5.1 Introduction
The Christie Proton Therapy Centre is a new facility under construction with the aim of
treating the first patient in 2018. The proton therapy centre is designed to deliver proton
beams with energy up to 250 MeV. The facility is planned to have 3 treatment rooms
and 1 research room. The treatment rooms will be fitted with a Varian ProBeam System
which will provide pencil beam scanning and a 360◦ rotating gantry. The research room
is planned to have 2 fixed beam lines, one for radiobiological studies and one for technical
investigations. All four rooms are attached to a cyclotron, as shown in figure 5.1, that
has an intensity of 10 nA [9, 109, 113].
Due to the fact that the rooms will be irradiated with high energy protons, radiation
protection studies need to be done in order to ensure that the safety limitations comply
with the law, and that the radiation dose is kept as low as reasonably practicable.
The aim of this project is to conduct radiation protection studies for the research room.
In order to do that, the ambient dose equivalent for secondary particles (neutrons and
photons) and the residual dose rates have been calculated at some of the points of
interest, such as the isocentre, the maze, the corridor, the facility room and the adjacent
treatment room. The ambient dose equivalents for neutrons and photons were calculated
for proton beams with several energies 70 MeV, 100 MeV, 150 MeV, 200 MeV and 250
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Figure 5.1: Christie Proton Therapy Centre design. Taken from [109].
MeV. In addition to secondary dose rates, the generation of radioactive nuclides within
the air and in the steel floor is also described in this chapter.
5.2 The simulations
For all the studies presented in this chapter, the FLUKA Monte Carlo code was used.
The default PRECISIO was used for all simulations. This option uses transport cuts of
100 keV for electrons, positrons and photons. The neutrons are transported down to
thermal energies [93]. The electromagnetic physics was described by the EMF package,
while the Boltzmann master equation (BME) theory was used to describe the hadronic
interactions. The hadron-nucleus nuclear interactions were treated by the PEANUT
(PreEquilibrium-Approach-to-Nuclear-Thermalization) nuclear interaction model [88].
All these FLUKA options are explained in chapter 3.
The simulations were made with a set of five runs, every run with 106 primary protons,
giving a total of 5 × 106 primary protons. This number was used to obtain good
statistics [89, 92] with a reasonable running time: 4 hours up to 48 hours, depending
on the ion species, energy and scoring type [93]. For radiation protection purposes,
the AMB74 option was used. The AMB74 is a set of coefficients for ambient dose
equivalent implemented for photons and electrons by ICRP74 and M. Pellicioni [94, 95].
The results of neutron ambient dose equivalent were compared with MCNPX results
taken from [113]. For air and floor activation and also for residual dose equivalent, the
IRRPROFI option was used to define the irradiation profile, while RESNUCLE and
DCYSCORE options were used to estimate the activity of the residual nuclei produced
in the stainless steel floor and in air. The neutron and photon ambient dose equivalent
rates were calculated using the USRBIN, DCYSCORE and AUXSCORE options. The
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results of the ambient dose equivalent are given in µSv/hour [93]. The input file used
for the evaluation of the ambient dose equivalent is presented in appendix.
In order to be able to compare shielding requirements needed in the proton treatment
range, a proton beam with an energy of 70, 100, 150, 200 and 250 MeV was simulated.
The beam is considered to be mono-energetic. The intensity is presumed to be 0.44 nA.
This corresponds to 2.75× 109 protons per second [109].
The beam line is assumed to be 150 cm above the floor level and to be perfectly horizontal
[109]. It enters the research room under a 60 degrees angle. These information was
provided as primary details for the simulations but later designs changed the height of
the beam line to 125 cm above the floor with the beam entering perpendicular to the
wall. This will not greatly affect the results.
Figure 5.2 represents the research room model as built with the FLAIR interface for
FLUKA as described in chapter 3. Figure 5.3 represents the elevation view at the max-
imum height of Y = 5 metres and the maximum length of Z = 30 metres, including the
maze corridor. The FLUKA model was designed according to the last civil engineering
plans that were used at the building of the facility [110]. Small differences regarding
the walls’ angles and maze dimensions may exist due to the fact that is not possible to
model the exact physical geometry in terms of fixed shapes and regions as required in a
Monte Carlo code. No ceiling was added in the model for clarity.
The materials used in the FLUKA simulations are shown in the table 5.1.
Structure Material Density (g/cm3)
Walls Concrete 2.34
Beam tube Aluminum 2.70
Target Graphite 2.26
Room Air 0.00120484
Floor Stainless Steel 8.0
Table 5.1: Materials used in the FLUKA geometry.
The beam line is modelled as a 10 m long Aluminium pipe, with an outer radius of 5
cm and a thickness of 2 mm. These dimensions were assumed as it is not yet known the
exact dimensions that will be used. They are typical for a fixed proton beam line used for
research purposes. Inside the beam pipe, it is assumed to be vacuum. The quadrupole
magnets that would normally be present to focus the proton beam are omitted, as
they introduce unnecessary complexity in the geometry, with a negligible effect on the
external radiation fields.
After passing the beam tube, the beam impinges a graphite phantom (10 × 10 × 45
cm) with the longest dimension in the beam direction. The graphite phantom length
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Figure 5.2: The layout of the research room as modelled in FLUKA. The positions
of the detectors: (1), (2), (3), (4) and (5) are shown.
Figure 5.3: The elevation view of the research room as modelled in FLUKA with the
maximum height of Y = 5 m and the maximum length of Z = 30 m.
is appropriate for a proton beam with an energy of 250 MeV in order to stop all the
protons from the proton beam as the maximum range for a proton beam with an energy
of 250 MeV is approximately 40 cm [125]. The phantom is made of graphite as this is
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typically used for calibration of a proton beam. A false floor was also included and it
has the role to sustain the weight of the beam line components. This is 2.5 cm thick
and is made of stainless steel. The floor is extended up to the maze corridor.
The ambient dose equivalent was calculated in several points of interest: the phantom
(at the isocentre) (1), the maze (2), the corridor (3), the facility room (4) and the
adjacent treatment room (5). The isocentre was chosen in order to be able to compare
the results with the calculations performed for the NHS treatment rooms. All these
points of interest where the dose was calculated are marked in figure 5.2. The floor is
also included in the FLUKA model. Next to the research room the facility rooms and
one of the treatment room will be placed.
5.3 Results
5.3.1 Neutron and photon dose equivalent
In radiation protection, the secondary particles that are of most interest are neutrons and
high energy photons (0.1-10 MeV) [111, 112]. The neutrons represent the main concern
as they are relatively abundant and highly penetrating [24]. It is very important to
calculate the neutron and photon dose equivalent in the research room, as the facility
room and one of the treatment rooms are adjacent.
The position of the detectors can be seen in figure 5.2. The particle transport threshold
is set at 100 keV. The simulation geometry as built in FLUKA is also shown in figure
5.2. The proton beam enters the research room and passes through the aluminium pipe
before impinging the graphite phantom.
Figure 5.4 shows the predicted neutron dose from a 70 MeV proton beam. The neutron
dose equivalent around the beam line and at the isocentre is around 50 µSv/h and at
the maze level it decreases to 1 µ Sv/h. Outside the shielding walls, at the points of
interest like the facility room, the corridor and the treatment room, the neutron dose
equivalent is less than 1 µ Sv/h. The photon dose equivalent follows the same pattern.
The photon ambient dose equivalent is high around the aluminium beam line and the
graphite phantom, approximately 10 µ Sv/h, and decreases to 0.1 µ Sv/h at the maze
and the facility room and 0.05 µ Sv/h on the corridor and the treatment room as shown
in figure 5.5. These values indicate that for a 70 MeV proton beam, in the areas of
interest, the neutron and photon ambient dose equivalent is low and can be regarded
as safe for employees or member of public as the dose rate is lower than the limits
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recommended by the IRR99 [40] for uniform irradiation of the whole body: 6-20 mSv/y
for radiation workers and 1 mSv/y for other personnel.
Figure 5.4: Neutron dose equivalent for a 70 MeV proton beam in the research room.
Figure 5.5: Photon dose equivalent for a 70 MeV proton beam in the research room.
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The results of the neutron dose equivalent are shown in an elevation view and the photon
dose equivalent in a plan view. This is merely for reasons of presentation and consistency,
and wishing to show both views without adding a large number of plots shown. For each
beam energy the shapes of neutron and photon dose distributions are broadly the same,
differing only in overall intensity.
For 100 MeV, as shown in figure 5.6, the neutron dose equivalent increases to 200 µ
Sv/h at the isocentre, while at the maze, the dose is 10 µ Sv/h. Outside the research
room, the dose decreases to 1 µ Sv/h in the corridor and in the treatment room. In the
facility room, the dose reaches 5 µ Sv/h. For photons, as shown in figure 5.7, the dose is
lower. At the isocentre it is 50 µ Sv/h and in the maze it is 0.5 µ Sv/h. In the corridor,
the dose is around 0.5 µ Sv/h, the same as in the treatment room, while in the facility
room, the dose is higher, around 1 µ Sv/h. As the particles are hitting the Aluminium
beam pipe and due to the fact that the beam pipe is shown in such a small scale, the
photon dose is shown as a line.
Figure 5.6: Neutron dose equivalent for a 100 MeV proton beam in the research room.
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Figure 5.7: Photon dose equivalent for a 100 MeV proton beam in the research room.
Increasing the proton beam energy to 150 MeV, the neutron ambient dose equivalent at
the isocentre increases up to 103 µ Sv/h, while in the maze area, the dose is around 10 µ
Sv/h as shown in figure 5.8. In the corridor and in the treatment room, the neutron dose
is around 1 µ Sv/h, while in the facility room, it was found to be 8 µ Sv/h. Comparing
figure 5.6 and figure 5.8, it should be noticed that the colour scale is changed, as the
maximum value changes from 1000 µ Sv/h to 10000 µ Sv/h. This is a feature of the
FLUKA code.
The photon ambient dose equivalent is increased as well to 5×104 µ Sv/h at the isocentre
and decreases to 7 µ Sv/h in the maze, 1 µ Sv/h on the corridor and in the treatment
room and approximately 10 µ Sv/h in the facility room as shown in figure 5.9. The dose
of the high energy photons is 50 times higher than that of the neutrons at the beam line
level, although the overall influence of the photon dose at the periphery of the research
room is not large. The same effect can be observed at 200 MeV and 250 MeV as shown
in figures 5.11 and 5.13.
Radiation Protection Studies for Radiobiology 73
Figure 5.8: Neutron dose equivalent for a 150 MeV proton beam in the research room.
Figure 5.9: Photon dose equivalent for a 150 MeV proton beam in the research room.
At 200 MeV, the neutron dose equivalent is around 2 ×103 µ Sv/h around the isocentre
and approximately 10 µSv/h in the maze. Outside the shielding walls, the dose is 5
µ Sv/h in the corridor and in the treatment room and around 8 µSv/h in the facility
room as shown in figure 5.10. The photon ambient dose equivalent was found to be
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7×104 µSv/h at the isocentre, 10 µSv/h in the maze, 5 µSv/h on the corridor and in
the treatment room and 50 µSv/h in the facility room as shown in figure 5.11.
Figure 5.10: Neutron dose equivalent for a 200 MeV proton beam in the research
room.
Figure 5.11: Photon dose equivalent for a 200 MeV proton beam in the research
room.
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At the maximum energy (250 MeV), the neutron dose equivalent is approximately 6
×103 µSv/h at the isocentre, 80 µSv/h in the maze and 8 µSv/h in the corridor and
in the treatment room, while in the facility room, the dose is 10 µSv/h as shown in
figure 5.12. The photon dose equivalent is 8 ×104 µSv/h at the isocentre, 50 µSv/h
in the maze and approximately 10 µSv/h in the accessible areas around the research
room. If we consider that the irradiation time is approximately 520 hours per year,
the neutron dose received by a worker in one year is approximately 41 mSv/year if the
person is present all 520 hours in the maze while the accelerator is operating, which is
an unrealistic scenario. Therefore, even at the maximum energy the neutron dose values
can be regarded as sufficiently low as the local regulations for controlled and public areas
limits introduced by IRR99 are: 20 mSv in a calendar year for employees aged 18 years
or over and 1 mSv in a calendar year for members of the public. However, it will be
useful to assess the radiation exposure using radiation monitors.
Figure 5.12: Neutron dose equivalent for a 250 MeV proton beam in the research
room.
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Figure 5.13: Photon dose equivalent for a 250 MeV proton beam in the research
room.
The FLUKA results were compared with MCNPX results obtained by Alex Flynn, an
MSc student from Manchester University as part of his dissertation. The results obtained
are presented in Ref.[113]. The MCNPX results are presented in mSv/year. In the model
considered in [113], the annual irradiation time is 520 hours. The results obtained with
the Monte Carlo codes are presented in table 5.2.
Structure Dose in FLUKA (mSv/year) Dose in MCNPX (mSv/year)
Maze 2.5 1.36
Corridor 2.0 1.44
Facility 5.0 3.54
Treatment room 1.5 0.01
Table 5.2: Annual effective dose rates obtained with FLUKA and MCNPX at 250
MeV beam energy.
The comparison between the FLUKA and the MCNPX showed that the values calculated
with FLUKA are higher than the values calculated with MCNPX. In the maze, the dose
equivalent calculated with FLUKA is 1 mSv higher than the dose equivalent calculated
with MCNPX, while on the corridor, the dose equivalent has approximately the same
value for both codes. The dose in the treatment room was found to be 100 times
higher with FLUKA. This is a big difference and the explanation is not clear: it could
be due to a significant difference between the materials and/or geometry used in the
two simulations. The FLUKA dose in the treatment room is lower than the other
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points recorded, but not by very much, whereas in MCNPX the dose in this location
is a factor of one hundred smaller than the others: something very different is being
described. Nevertheless, these are results based on an early and simplified geometry and
an additional set of simulations should be done with a more detailed geometry.
5.3.2 Study of radioactivity induced in the research room
As a result of nuclear interactions, radioactive nuclei will be produced due to the proton
interactions with the surrounding materials. The decay of these radionuclides produces
a source of radiation, therefore, the study of radioactivity induced in the treatment/re-
search room is very important aspect as this represents a potential radiation hazard
to personnel or patients [111]. Calculations have been carried out to determine the
residual dose rate in the research room as a function of time after irradiation. Using
the FLUKA code, the beam was simulated to pass through an Aluminium beam pipe
before hitting the graphite phantom with three different energies (70 MeV, 150 MeV,
250 MeV) and for four different cooling times: after irradiation, 1 hour, 1 month, 1 year.
The electromagnetic cascade was turned on (EMF-ON) together with the RADDECAY
card in order to allow the calculation of the residual dose rates based on the production
of radioactive isotopes. The EVAPORATION and COALESCENCE models were also
activated using the PHYSICS card for accurate description of the nuclear processes and
to obtain the residual nuclei production [92, 93]. These FLUKA options were described
in chapter 3. For all studies, the irradiation profile chosen for this set of simulation was
1.4 hours per day (approximately 10 hours per week) [113] of irradiation at maximum
intensity.
We have to consider separately the activation of air and the activation of the concrete,
beam pipe and other materials. The difference is that the air may move through the
ventilation system, while all other components will stay fixed. The air activation will be
considered first.
As mentioned in 4.3.5 when protons interact with matter, they will produce fast neutrons
which will interact with the atoms from air, producing short-lived radionuclides. Table
5.3 lists the isotopes found most abundantly in the atmosphere [126]. After multiple
collisions, the fast neutrons will slow down to thermal energies producing 15O, 13N, 11C
and 7Be from collisions with the oxygen, nitrogen and carbon atoms from air [107].
The thermal neutrons will also be captured by 40Ar from the air and radioactive 41Ar
will be produced. 41Ar is a beta and gamma emitter and is well-known to be the
major contributor to the air activation [107, 108]. The clinical staff are likely to receive
more dose equivalent from radionuclides with half lives of the order of 15-20 min than
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Isotope Percentage by volume in the atmoshere
14N 78.1
16O 21.2
40Ar 0.46
15N 0.28
18O 0.04
12C 0.015
17O 0.008
36Ar 0.0016
Table 5.3: The most abundant isotopes found in the atmosphere.
Isotope T 1/2 A (Bq) A (Bq) A (Bq) Limit
from
IRR99
(Bq)
70 MeV 150 MeV 250 MeV
41Ar 109.61 m 5.9×102 3.4×103 8.9×103 109
15O 122.2 s 2.5×105 4.8×105 8×105 109
13N 9.96 m 4.7×105 5.8×105 9.5×105 109
11C 20.33 m 7.2×105 9.6×105 1.3×106 106
7Be 53.28 d 1.1×104 1.5×104 2.3×104 107
Table 5.4: The most abundant radionuclides present in air after irradiation for 70
MeV, 150 MeV and 250 MeV proton beams with he limits allowed by IRR99 [40].
from shorter- or longer-lived radionuclides, according to Knowles, Orthel and Hill [111].
Therefore, the resulting activity of the most important isotopes and the ones considered
harmful are shown in table 5.4.
a) Immediately (after irradiation)
Immediately after irradiation at 70 MeV the most abundant isotopes are 15O, 13N and
11C, while at 150 MeV it was found that the activity of 41Ar increased, simultaneously
with the activity of 15O, 13N and 11C. For most radioisotopes at most energies, the ac-
tivity induced in the research room air is below the limits given in IRR99 [40]. However,
if the accelerator is operated at maximum energy, 11C will exceed the limit as shown in
table 5.4. Under these circumstances personnel should not have access to the research
room until a cooling-off period, commensurate with the 20 minute half-life, has elapsed.
Apart from that, these results demonstrate that the research room has a low risk of con-
tamination and the personnel will not be exposed as the activity of the most important
radioisotopes is below the legal limits suggested in the IRR99 [40].
b) 1 hour (after irradiation)
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After 1 hour of cooling time, the activities of the most radioactive radioisotopes like:
13N, 11C will decrease by several factors of 2, while the 41Ar falls off more slowly as
shown in table 5.5.
Isotope T 1/2 A (Bq) A (Bq) A (Bq) Limit
from
IRR99
(Bq)
70 MeV 150 MeV 250 MeV
41Ar 109.61 m 4.1×102 2.3×103 6.1×103 109
15O 122.2 s 3.5×10−4 6.6×10−4 1.09×10−3 109
13N 9.96 m 7.3×103 9×103 1.4×104 109
11C 20.33 m 9.3×104 1.2×105 1.7×105 106
7Be 53.28 d 1.1×104 1.5×104 2.3×104 107
Table 5.5: The most abundant radionuclides present in air after 1 hour of cooling for
70 MeV, 150 MeV and 250 MeV proton beams with the limits allowed by IRR99 [40].
After 1 month, the activity of the medium half-live radionuclides as 41Ar will consider-
ably decrease down to 10−9 Bq. Therefore, the activity of the isotopes, after 1 month
and 1 year of cooling time, are not presented as the activity is negligible.
Overall, these results demonstrate that, immediately after irradiation, the personnel
working in the research room will not be exposed to radiation exposure as the radioac-
tivity is below the legal limits presented in IRR99.[40] Therefore, no additional mitiga-
tion is considered necessary for irradiation of the air in the research room. However,
the activity must of course be monitored. Nevertheless, these results are based on early
information and simplified geometry and for effective dose assessment more information
is required like: calculations for the entire machine, volume of the air and ventilation
parameters.
The next task was to calculate the residual dose equivalent rate in the research room
due to the activation of the beam pipe, graphite phantom, concrete and air (the air is
also included in the simulations). For aluminium beam pipe, the main contributors to
the dose rate are: 18Fe, 24Na and 22Na. For concrete, the main contributor to the dose
rate is 24Na. The calculations have been performed using the same irradiation profile
as before: 1.4 hours per day (approximately 10 hours per week) [113] of irradiation at
maximum intensity, for a proton beam with different energies and for six periods of
cooling time: after irradiation, 1 hour, 1 day, 1 month, 3 months and 1 year. The dose
rate is normalized in terms of µSv/h. For a 70 MeV proton beam, the residual dose
equivalent in the research room immediately after irradiation is shown in figure 5.14.
The plots suggest that the residual dose is higher in the beam line direction and decreases
with distance. Immediately after irradiation, the residual dose in the direction of the
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Figure 5.14: Residual dose equivalent in beam pipe, graphite phantom, concrete and
air after irradiation with a 70 MeV proton beam.
beam line is approximately 20 µSv/h, around 10 µSv/h in the maze and 1 µSv/h around
the shielding walls, even in the adjacent treatment room. In the corridor, the residual
dose is around 10−4 µSv/h which is negligible.
After 1 hour of cooling time, the residual dose has a value of 1 µSv/h around the isocentre
and 0.1 µSv/h in the maze. The dose falls to 0.5 µSv/h after the shielding walls in the
adjacent rooms as shown in figure 5.15. These values indicate that for a 70 MeV proton
beam, the residual dose is low, even immediately after irradiation. Therefore, it is safe
for workers to access the research room immediately after the irradiation sessions and
also for members of public who are in the adjacent areas.
The residual dose equivalent was calculated also after 1 day and 1 month of cooling time.
The results shows that after 1 day the residual dose around the isocentre decreases down
to 10−2 µSv/h and at the shielding wall and on the corridor the dose goes down to 10−5
µSv/h as shown in figure 5.16. After 1 month, the results showed that the dose decreased
significantly. In the research room, the residual dose is 10−4 µSv/h and outside the room,
it is approximately 10−6 µSv/h as shown in figure 5.17. These results suggest that after
1 day and 1 month of cooling time, the residual dose decreases significantly and the staff
working outside the shielding walls will not be exposed to radiation.
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Figure 5.15: Residual dose equivalent in beam pipe, graphite phantom, concrete and
air after 1 hour of cooling for a 70 MeV proton beam.
Figure 5.16: Residual dose equivalent in air after 1 day of cooling at 70 MeV proton
beam.
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Figure 5.17: Residual dose equivalent in beam pipe, graphite phantom, concrete and
air after 1 month of cooling at 70 MeV proton beam.
The residual dose was also calculated at 3 months and 1 year after irradiation to consider
the cumulative effect of many experiments over a period of time and also because it is
an important aspect for decommissioning. As expected, the doses around the beam line
are 10−5 µSv/h and 10−7 µSv/h respectively. At the shielding walls and in the adjacent
rooms, the residual dose decreased to 10−8 µSv/h after 3 months and is essentially zero
after 1 year.
All these results prove that for a 70 MeV proton beam, the residual dose is low after
irradiation. Therefore, members of public and the staff working in the research room
will not be exposed to high radiation.
At 150 MeV, the residual dose equivalent in air immediately after irradiation is shown in
figure 5.18. The results show that at the isocentre the residual dose is around 10 µSv/h
and it decreases gradually with distance. In the maze corridor the dose is 0.5 µSv/h and
approximately 10−2 µSv/h in the facility room. The radiation passes the shielding walls
and is attenuated by the concrete walls. The residual dose in the adjacent treatment
room is 10−2 µSv/h near the shielding walls and 10−3 µSv/h further down. The residual
dose has the same value in the corridor.
After 1 hour from irradiation, the residual dose equivalent around the isocentre decreases
to 0.1 µSv/h and to 10−3 µSv/h in the maze corridor as shown in figure 5.19. Outside the
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Figure 5.18: Residual dose equivalent in beam pipe, graphite phantom, concrete and
air after irradiation for a 150 MeV proton beam.
shielding walls, in the treatment room, the residual dose is 10−4 µSv/h near the shielding
walls and decreases to 10−5 µSv/h at a distance of a few metres. In the corridor, the
residual dose is 10−4 µSv/h.
After 1 day, the residual dose at the isocentre and along the beam line decreases to 10−2
µSv/h. In the remaining space of the research room, the residual dose is 10−3 µ Sv/h.
In the maze and at the exterior of the shielding walls, the residual dose is 10−3 µSv/h.
In the corridor, the residual dose decreases to 10−6 µSv/h as shown in figure 5.20.
After 1 month from irradiation, the results show that the dose is significantly lower
than after 1 day. This is understandable as the isotopes produced due to the beam line
activation have a T 1/2 shorter than 1 month. In the research room, the residual dose
is 10−3 µSv/h and outside the shielding walls and at the points of interest, the dose is
10−7 µSv/h as shown in figure 5.21.
The residual dose after 3 months of cooling is significantly low, even around the beam
line the dose is 10−4 µSv/h and outside the shielding walls the dose decreases down to
10−8 µSv/h. After 1 year, the residual dose was found to have approximately the same
value as after 3 months of cooling.
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Figure 5.19: Residual dose equivalent in beam pipe, graphite phantom, concrete and
air after 1 hour of cooling for a 150 MeV proton beam.
Figure 5.20: Ambient dose equivalent in beam pipe, graphite phantom, concrete and
air after 1 day of cooling for a 150 MeV proton beam.
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Figure 5.21: Residual dose equivalent in beam pipe, graphite phantom, concrete and
air after 1 month of cooling for a 150 MeV proton beam.
In conclusion, for a 150 MeV proton beam, the residual dose in the research room due
to the beam line activation after irradiation is relatively high, but outside the shielding
walls the residual dose is low, 10−2 µSv/h. After 1 hour the residual dose decreases to
0.1 µSv/h in the research room and 10−4 µSv/h outside the research room. Therefore,
the access of the staff in the research room, immediately after irradiation, it is permitted
as well the access of public in the corridor or to the facility room.
The residual dose was calculated also for a 250 MeV proton beam. After the irradiation,
the results showed that the residual dose at the isocentre is high and reaches 50 µSv/h
and 5 µSv/h at the shielding wall behind the isocentre. In the maze, the residual dose
has a value of 0.1 µSv/h. Outside the shielding walls, in the corridor the residual dose
is 10−2 µSv/h as shown in figure 5.22. These results suggest that the access of the
employees and members of public should not be limited as the dose values are below the
limits suggested by the UK regulations [40].
After 1 hour, the residual dose at the isocentre decreases to 0.5 µSv/h and 10−2 µSv/h
in the vicinity. At the point of interest, the residual dose is 10−3 µSv/h at the maze and
10−4 on the corridor µSv/h as shown in figure 5.23.
After 1 day, the residual dose in the research room is 0.05 µSv/h and outside the shielding
walls, the residual dose decreases to 10−3 µSv/h in the maze and to 10−5 µSv/h on the
corridor as shown in figure 5.24. After one month of cooling, the residual dose decreases
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Figure 5.22: Residual dose equivalent in beam pipe, graphite phantom, concrete and
air after irradiation with a 250 MeV proton beam.
Figure 5.23: Residual dose equivalent in beam pipe, graphite phantom, concrete and
air after 1 hour of cooling for a 250 MeV proton beam.
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considerably to 10−3 µSv/h at the isocentre, 10−5 µSv/h in the maze and 10−6 µSv/h
on the corridor as shown in figure 5.25.
Figure 5.24: Residual dose equivalent in beam pipe, graphite phantom, concrete and
air after 1 day of cooling for a 250 MeV proton beam.
Figure 5.25: Residual dose equivalent in beam pipe, graphite phantom, concrete and
air after 1 month of cooling for a 250 MeV proton beam.
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After 3 months the residual dose in the research room is 10−4 µSv/h and outside the
shielding walls is 10−7 µSv/h. In one year’s time, the dose decreases to 10−5 µSv/h
around the beam line and 10−6 µSv/h in the vicinity. Outside the shielding walls the
residual dose was found to be 10−8 µSv/h.
The results obtained for the residual dose rate in the research room suggest that if the
proton beam runs at the maximum energy of 250 MeV, immediately after irradiation,
the dose is found to be approximately 50 µSv/h at the isocentre and 10−2 µSv/h outside
the shielding walls. These values are low enough not to request additional mitigation
methods as the limits suggested by the UK regulations are fulfilled [40].
The next task was to calculate the radioactivity induced in the floor. The same irradi-
ation profile as above was used. The floor is 2.5 cm thick and is made of stainless steel.
In FLUKA, the typical stainless steel has a composition of 18% 24Cr, 74% 26Fe and 8%
28Ni. The floor does not include the maze. The results are presented in table 5.6 and
include only the isotopes with high activity and medium and long half-lives.
a) Immediately (after irradiation)
The results suggest that, immediately after irradiation, the highest activity will be be
given by 58Co, 57Ni, 56Mn, 55Co, 51Cr, 51Mn and 49Cr but at 70 MeV and 150 MeV, the
activity of these radioisotopes will not reach the limits suggested by the UK regulations
[40]. At 250 MeV, only the activity of 56Mn exceeds the limit. Therefore, at maximum
energy, the radioactivity induced in the stainless steel floor is below the limits suggested
in IRR99 [40], hence the stainless steel floor do not represent a hazard.
b) Cooling time 1 hour (after irradiation)
After 1 hour of cooling, the activity of the radionucliedes mentioned before is decreasing
and even at maximum energy, the activity will not exceed the limits as shown in table
5.7.
c) Cooling time 1 month (after irradiation)
After 1 month, the activity of several radioisotopes will decrease significantly down to
3.929017 × 10−17 Bq for 55Co. Therefore, the results for the activity after one month
and one year cooling time are not presented as the levels are insignificant.
This study showed that the activation of the stainless steel floor does not represent
a factor of exposure for personnel, as the activity is low when compared with the air
present in a normal 100 sq meter European home which has up to 30,000 Bq [114].
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Isotope T 1/2 A (Bq) A (Bq) A (Bq) Limit
from
IRR99
(Bq)
[40]
70 MeV 150 MeV 250 MeV
65Ni 2.5172 h - 5.9×102 2.1×103 106
61Co 1.650 h 4.0×102 1.2×103 5.8×103 106
60Cu 23.7 m - - 2.8 × 103 105
58Co 70.86 d 1.1×103 4×103 6.8×103 106
57Co 271.74 d 2.1×102 9.6×102 2.2×103 106
57Ni 35.60 h 2.3×103 104 3×104 106
56Mn 2.5789 h 6.1×104 2.7×105 5.8×105 105
56Co 77.233 d 3.8×102 2×103 5.2×103 105
56Ni 6.075 d - 5.7×102 1.7×103 106
55Fe 2.737 y 3.6×102 1.7×103 3.9×103 106
55Co 17.53 h 2.1×103 1.3×104 3.2×104 106
54Mn 312.03 d 4.1×102 2.6×103 6.5×103 106
52Mn 5.591 d 9.8×102 1.3×104 4.6×104 105
52Fe 8.275 h 2.6×102 1.9×103 6.2×103 106
51Cr 27.7025 d 5.0×103 2.6×104 7.3×104 107
51Mn 46.2 m 1.8×103 2.2×104 8.9×104 105
49Cr 42.3 m 2.2×103 3.2×104 1.1×105 106
49V 329 d - 8×102 2.7×103 107
48V 15.9735 d 1.6×102 4.8×103 2.1×104 105
48Cr 21.56 h - 1.4×103 5.3×103 106
47V 32.6 m - 5.8×103 3×104 105
45Ti 184.8 m - 5.5×103 3.3×104 106
44Sc 3.97 h - 3.5×103 9.2×103 105
43Sc 3.891 h - 9.8×103 9.2×104 106
42K 12.360 h - - 2.4×103 106
24Na 14.9590 h - - 1.1×103 105
Table 5.6: The most abundant radionuclides in the floor after irradiation for 70 MeV,
150 MeV and 250 MeV proton beams with the limits allowed by IRR99 [40].
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Isotope T 1/2 A (Bq) A (Bq) A (Bq) Limit
from
IRR99
(Bq)
[40]
70 MeV 150 MeV 250 MeV
65Ni 2.5172 h - 4.5×102 1.6×103 106
61Co 1.650 h 1.5×102 7.8×102 3.8×103 106
58Co 70.86 d 1.1×103 4×103 6.8×103 106
60Cu 23.7 m - - 24.8×102 105
57Co 271.74 d 2.1×102 9.6×102 2.2×103 106
57Ni 35.60 h 2.3×103 104 3×104 106
56Mn 2.5789 h 4.6×104 2×105 4.4×105 105
56Co 77.233 d 3.8×102 2×103 5.2×103 105
56Ni 6.075 d - 5.6×102 1.7×103 107
55Fe 2.737 y 3.6×102 1.2×103 3.9×103 106
55Co 17.53 h 2×103 1.7×103 3.1×104 106
54Mn 312.03 d 4.1×102 2.6×103 6.5×103 106
52Mn 5.591 d 9.7×102 1.3×104 4.6×104 105
52Fe 8.275 h 2.4×102 1.7×103 5.7×103 106
51Cr 27.7025 d 5×103 2.6×104 7.3×104 107
51Mn 46.2 m 7.3×102 9.2×103 3.6×104 105
49V 329 d - 8×102 2.7×103 107
49Cr 42.3 m 8.2×102 1.2×104 4.3×104 106
48V 15.9735 d 1.6×102 4.8×103 2.1×104 105
48Cr 21.56 h - 1.4×103 5.2×103 106
47V 32.6 m - 1.6×103 8.5×103 105
45Ti 184.8 m - 4.4×103 2.6×104 106
43Sc 3.891 h - 8.26×02 7.7×103 106
42K 12.360 h - - 2.3×103 106
24Na 14.9590 h - - 1×103 105
Table 5.7: The most abundant radionuclides in the floor after 1 hour for 70 MeV,
150 MeV and 250 MeV proton beams with the limits allowed by IRR99 [40].
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5.4 Conclusion
The prompt ambient dose equivalent for neutrons and photons was calculated for dif-
ferent points of interest like the phantom (isocentre), the maze, the corridor and the
treatment room for different energies 70 MeV, 100 MeV, 150 MeV, 200 MeV and 250
MeV. The results showed that the secondary dose increases with energy, especially in
the direction of the beam line. At the minimum energy of 70 MeV, the neutron dose
equivalent at the isocentre was found to be around 50 µSv/h and it decreases with dis-
tance. At the maze level the neutron dose was found to be 1 µSv/h and is even lower
on the corridor and the adjacent treatment room. The photon dose was found to be
approximately 10 µSv/h around isocentre and 0.1 µSv/h outside the shielding walls, at
the facility room (point 4), while in the corridor it was found to be 0.05 µSv/h. Hence,
for a 70 MeV proton beam, the neutron and the photon dose equivalent can be regarded
as safe for employees or members of public.
If the full proton beam were to be lost in the graphite phantom at the maximum energy
250 MeV, the neutron dose equivalent would be 6 mSv/h at the isocentre, 80 µSv/h
in the maze and 8 µSv/h in the accessible areas around the research room, while the
photon dose would be 80 mSv/h at the isocentre, 50 µSv/h in the maze and 10 µSv/h
in the areas around the research room.
As no person will stay 10 hours per week in the research room or in the maze when the
beam is on, these values can be regarded as sufficiently low for employees over 18 years
old. For the members of public, working in the accessible areas around the research
room, the access should be limited when the beam is on to comply with the legal limits
[40].
For the second set of simulations, the radioactivity induced in air, the beam pipe, con-
crete and other materials of the research room together with the residual dose rate was
studied. The irradiation profile was set for 10 hours of activity per week at full intensity
(2.75 × 109 protons/s). The results showed that, immediately after irradiation, the
residual dose equivalent in the research room is of the order of several µSv/h: 1 µSv/h
for 70 MeV and > 100 µSv/h for 250 MeV. After 1 hour, the value of the dose decreases
significantly down to 50 µSv/h for 250 MeV. After 3 months, the dose decays down
to 10−3 µSv/h. The results suggest that at 250 MeV the human intervention in the
research room should be kept to a minimum possible after irradiation, but after 1 hour
of cooling time, it will be safe for employees to access the room.
It should be noted that these results have been studied for the worst-case scenario, where
the maximum beam energy (250 MeV) is used for a period of 1 year. In addition, the
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irradiation profile was only presumed and the results will differ depending on the irradia-
tion scenario. Therefore, to obtain more realistic results, it is necessary to develop more
irradiation scenarios as detailed and complete as possible, but the results presented in
this chapter indicate that the radiation produced during the operation of the accelerator
will be well below the regulatory limits [40].
Chapter 6
Radiation protection studies for
the OpenMed/BioLeir facility
6.1 Introduction
The OpenMed/BioLeir project at CERN was proposed in 2010 and the proposal consists
in using the LEIR (the Low Energy Ion Ring) synchrotron, an existing facility at CERN,
to provide beams for experiments to support of cancer treatment centres [116]. The Low
Energy Ion Ring (LEIR) facility was proposed in 1993 and it accumulates heavy ions,
up to Pb54+, in order to achieve the required luminosity for collisions in the Large
Hadron Collider (LHC). LEIR was transformed from a previous synchrotron LEAR
(Low Energy Anti-proton Ring) used to decelerate and store anti-protons [116]. LEIR
was commissioned in 2005 and now the facility is part of the LHC injection, situated
between the Linear Accelerator 3 (LINAC3) and Proton Synchrotron (PS), as illustrated
in the figure 6.1.
Even though in Europe many clinics offer the possibility to treat cancer with hadron
therapy, beam line time for pre-clinical radiation biology, chemistry, physics studies
and for radiological experiments is limited so an additional facility is highly desirable.
Therefore detailed studies should be done.
The motivation of using LEIR for medical research is that the facility is not used all the
time for the LHC, therefore the provided beam could be used for the development of
accurate detectors to be used for dosimetry of active or passive beam delivery systems,
and for radiobiological experiments for different beam characteristics, ion species, cell
lines and tissue. The beam could also be used to study the interaction of ions with
93
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Figure 6.1: LHC injection chain [117].
different drugs used for chemotherapy or for developing more precise imaging techniques
which could be used to treat moving targets.
LEIR it is specially suitable for a biomedical research facility because it can provide the
space needed for experiments, as illustrated in figure 6.2. The LEIR machine occupies
only a small part of the hall and almost 1500 m2 could be used for the installation of
experimental systems [116].
Despite all these advantages, there are some limitations of the existing facility regarding
the requirements for radio-biological research. With the present main power supply,
the energy for 12C and 16O can reach only 240 MeV/n. To reach the maximum energy
used in hadron therapy of 400 MeV/n, the facility will need new power supply. The
magnets are suitable to reach this energy. This higher energy will increase the radiation
protection issues [119].
LEIR is the only accelerator at CERN with possible access for visitors during the machine
operation, via a platform installed above the shielding wall, as can be seen in figure 6.3.
The first and the only radiation protection calculations were made by Sanja Damjanovic
[120]. This work includes only the results for the present situation, where Pb, Xe and
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Figure 6.2: The LEIR facility layout [118].
Ar ions are accelerated as primary particles. In [120], the dose rates at the visitor
platform for different beam losses are presented for Pb, Xe and Ar ion species. The
results presented show that the dose at the visitor platform level will be between 0.45-2
µSv/h for these ion species and normal beam losses, while for a continuous full beam
loss, the ambient dose equivalent was found to be approximately 4.6 µSv/h. As the
visitor platform is classified as a supervised radiation area, the dose at this level should
not exceed 10 µSv/h according to the CERN regulations [48]. The results obtain in
[120] showed that, for the present situation, the public access to the platform would be
permitted. Any changes in operational conditions should be followed by new radiation
protection calculations as for Oxygen and Carbon ions with a beam energy of 250 MeV/n,
the dose at the visitor platform level is expected to reach 60 µSv/h for 1% beam losses
[120].
Using the same geometry as in [120], the aim of this work is to conduct radiation
protection studies using the future operational conditions at LEIR, and thus to establish
if the existing facility needs an additional roof on top of the machine when using ions
from protons up to Oxygen in the range of 1 to 250 MeV/n, and to see if the facility needs
extra shielding walls in order to protect the staff working in the adjacent laboratories
or the CMS control room.
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Figure 6.3: The LEIR visitor platform with the LEIR ring behind it [120].
The CERN’s radiation safety code [48] is based on international standards and it com-
plies with the IRR99 [40] dose limits:
• 20 mSv whole body annual dose for employees;
• 6 mSv whole body annual dose for trainees;
• 1 mSv whole body annual dose for the members of the public;
The ambient dose equivalent was calculated at three different heights: at the beam line
level of 1.7 metres, at 5 metres height where the roof might be placed and 6.5 metres
height at the visitor platform level. The dose at 1.7 m height was simulated with the
aim of calculating the possible dose received by the personnel working at the beam line
level for the maintenance of the machine. The dose at the roof level was calculated to
observe the difference of the dose value with roof and without and the dose at the visitor
platform level was calculated to establish if the dose exceeds the legal limit [48]. Figure
6.3 shows the visitor platform situated on top of the LEIR synchrotron.
As LEIR is planned to become a biomedical experimental facility, the machine will
accelerate protons and carbon ions. There is also a new interest for helium and oxygen
ions which are considered good candidates for future clinical use, as helium ions have a
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small lateral penumbra when compared with protons, and oxygen ions have a higher RBE
compared with carbon which make them a good candidate for radio-resistant tumours
[116]. Therefore the simulations were made for 1H, 4He, 12C and 16O ions with an energy
of 250 MeV and 250MeV/n respectively. This energy was chosen as this is the maximum
energy which can be provided with the current power supply [119].
6.2 The simulations
The essential aim of this project is to determine if the LEIR facility provides appro-
priate radiation shielding, especially at the visitor platform. The radiation around the
LEIR will be mainly formed by neutrons and gamma rays escaping from the radiation
sources like beam line components and air. The secondary particles can cause skyshine
exposure to members of staff working in the vicinity of the facility. The main goal of
the radiation protection calculations is to ensure that the dose equivalent is less than
3 µSv/h outside the shielding walls and less than 10 µSv/h at the visitor platform and
that the CERN Radiation Protection rules and regulations complied with: 6 mSv/y in
supervised radiation areas and 20 mSv/y in simple controlled radiation areas [48].
The ambient dose equivalent was calculated using the FLUKA Monte Carlo code [79, 86].
The FLUKA code was described in chapter 3. The PRECISIO default was used for all
simulation as it is used mainly for precision simulations. This default includes [93]:
• The transport of electrons, positrons and photons is activated;
• The Rayleigh scattering and Compton scattering profiles are activated;
• The neutrons are transported down to thermal energies;
• Fully analogue, the physical reality is simulated without giving any importance to
some of the geometry areas, absorption for low-energy neutrons;
• Particle transport threshold set at 100 keV, except for neutrons;
• Multiple scattering threshold at minimum allowed energy, for both primary and
secondary charged particles;
• Delta ray production on with threshold 100 keV;
• Heavy particle e+ e− pair production activated with full explicit production;
• Heavy fragment transport activated;
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The ambient dose equivalent for all particles was calculated using the USRBIN option to
score the distribution of the dose in the geometry provided and the AUXSCORE to set
the scoring detector and to choose the dose equivalent conversion factor. In this case, the
AMB74 option was chosen as it uses the dose equivalent conversion factor implemented
by ICRP74 [94] and M. Pellicioni [95]. The simulations were made for 12C, 16O, 4He and
1H and for three for three different beam loss rates: 1% (1.9 ×107 ions/s) and 20% (3.8
×108 ions/s) as these covers the range of losses experienced in normal conditions and
100% (1.9 ×109 ions/s) which represents full beam loss and is the worst-case scenario.
The ions are assumed to interact with the surface of the stainless steel beam tube with
the extraction energy (250 MeV). The impact point is localized in the beam direction
(at z=0) and randomly distributed. The stainless steel beam tube outer radius is Ro=
14.8 cm and the inner radius is Ri=14.5 cm. The accelerator structure and room were
designed with the FLAIR interface for FLUKA as shown in figures 6.4 and 6.5, using the
same model as in [120]. The height of the concrete walls is 4 m and the thickness is 1.6
m [120]. The concrete used at CERN has a density of 2.35 g/cm3 and a composition of
52.9% 16O, 3.37% 28Si, 1% 1H, 1.6% 23Na, 0.2% 24Mg, 3.4% 27Al, 0.1% 12C, 1.3% 39K,
4.4% 40Ca and 1.4% 56Fe. The concrete composition was provided by Vasilis Vlachoudis
from CERN.
Figure 6.4: FLUKA plan geometry of the accelerator room.
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Figure 6.5: Elevation view of the accelerator room with the concrete roof.
The materials used in the FLUKA simulations are shown in the table 6.1:
Structure Material Density (g/cm3)
Walls Concrete 2.35
Beam tube Stainless steel 8
Room Air 1.225 ×10−3
Table 6.1: Materials used in the FLUKA model.
As mentioned before, for radiation protection purposes, the ambient dose equivalent was
calculated at three different levels: at the beam line level (1.7 m), at the roof level (5
m) and at the platform level (6.5 m).
6.3 Results
Using the FLUKA Monte Carlo code together with FLAIR interface, the ambient dose
equivalent for secondary particles (neutron and gamma radiation) was calculated for 12C,
16O, 4He and 1H ion beams interacting with the stainless steel beam pipe in different
sections of the machine: the injection line (SS10), the second section along the shielding
wall (SS20), the extraction line (SS30)(see figure 6.6) with the maximum energy of 250
MeV and for three beam losses (1%, 20%, 100%). To reduce the number of scenarios
presented it was simulated 1% in SS10, 20% in SS20 and 100% in SS30.
Every simulation was performed with five runs of 106 primary particles, giving 5× 106
primary particles. The first set of simulations was made with no roof on top of the
machine, while for the second set a roof of 80 cm thickness of concrete was added. For
both set of simulations, three different simulations were run for all beam losses but I
have chosen to include only one image for every beam loss at different heights because
the results were very similar.
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Figure 6.6: The LEIR layout [117].
Hydrogen at 1%, 20%, 100% beam loss without roof
For a beam loss of 1% at the beam line level, when the 250 MeV proton beam passes
the injection line SS10, it interacts with the beam tube producing a high dose at the
interaction point of 102 µSv/h. At the chicane, the radiation dose is 1 µSv/h. Behind
the shielding walls the ambient dose equivalent is 0.1 µSv/h at the interaction point and
0.01 µSv/h in the laboratories space while at the visitor platform level, the dose is less
than 1 µSv/h, as seen in figure 6.7.
As the proton beam goes further, it interacts with SS20, the second section of the
beam line along the shielding wall. For a 20% beam loss in SS20, the dose level at the
interaction point is 104 µSv/h. At the roof level (5 metres above ground) the ambient
dose equivalent above the interaction point is 50 µSv/h, while above the chicane it is 1
µSv/h. At the visitor platform, the dose is around 5 µSv/h. Behind the shielding walls,
where the interaction occurs, the dose is 5 µSv/h and it decreases down to 0.5 µSv/h in
the research laboratory as shown in figure 6.8.
In SS30, for the worst case scenario when the entire beam is lost, the dose at the
interaction point is 105 µSv/h, while at the platform level (6.5 metres above the beam
line), the ambient dose equivalent is 60 µSv/h. Above the chicane the dose is low, 1
µSv/h and outside the shielding walls, where the interaction occurs, the dose equivalent
is approximately 5 µSv/h and 1 µSv/h in the laboratory as seen in figure 6.9.
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Figure 6.7: Ambient dose equivalent in SS10 for H at 1% beam loss.
Figure 6.8: Ambient dose equivalent in SS20 for H at 20% beam loss.
These results shows that for protons, at 1% and 20% beam losses, the dose at the visitor
platform is not higher than 5 µSv/h and in the laboratory the dose is 0.5 µSv/h, therefore
the legal limit is not exceeded [48]. In the worst-case scenario, if the entire beam is lost,
the dose at the visitor platform is 60 µSv/h, while in the lab it is around 5 µSv/h near
the shielding wall and 1 µSv/h in the remaining space. These findings suggest that if
the beam losses are higher than 20%, the dose limit allowed at the platform level will be
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exceeded, therefore, the area has to be classified as a limited stay radiation area [48] and
a roof on top of the machine will be required in order to decrease the dose at this point
unless an interlock system is added to stop the beam if the beam loss limit is exceeded.
Figure 6.9: Ambient dose equivalent in SS30 for H at 100% beam loss.
Helium at 1%, 20%, 100% beam loss without roof
When a 250 MeV helium ion beam interacts with the SS10 injection line, at the beam line
level the dose at the interaction point is 50 µSv/h for 1% beam loss. At the chicane, the
ambient dose equivalent is 1 µSv/h. Behind the shielding wall including the laboratory,
the ambient dose equivalent is 10−2 µSv/h as presented in figure 6.10. At the roof level,
the dose is 1 µSv/h, while at the platform level it is approximately 0.5 µSv/h.
If the beam losses are increased to 20% in SS20, the dose at the interaction point is 102
µSv/h. At the roof level (5 metres above the ground), the ambient dose equivalent is 10
µSv/h above the interaction point. Behind the shielding walls, in the direction of the
interaction point, the dose is less than 1 µSv/h and 0.5 µSv/h in the research laboratory.
At the platform level, the dose is 5 µSv/h as shown in figure 6.11.
When the entire beam is lost in SS30, the dose at the interaction point is 500 µSv/h and
at the visitor platform it is 50 µSv/h. Behind the shielding wall, near the point where
interaction occurs, the ambient dose equivalent is 1 µSv/h and decreases to 0.5 µSv/h
as we move further away from the interaction point, as shown in figure 6.12.
These calculations suggest that, for 20% beam losses, the dose at the visitor platform
is safe and no additional protection should be added as well the dose in the research
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Figure 6.10: Ambient dose equivalent in SS10 for He at 1% beam loss.
Figure 6.11: Ambient dose equivalent in SS20 for He at 20% beam loss.
laboratory, while at 100% beam losses, the dose at this level is 50 µSv/h, and 0.5 µSv/h
in the laboratory, therefore a roof should be placed on top of the machine to protect the
visitor against an eventual total beam loss.
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Figure 6.12: Ambient dose equivalent in SS30 for He at 100% beam loss.
Carbon at 1%, 20%, 100% beam loss without roof
The ambient dose equivalent was also calculated for a 250 MeV/n carbon beam, in-
teracting with the beam pipe. For 1% beam loss in SS10, the dose at the interaction
point is 500 µSv/h. Behind the shielding wall at the interaction point, the dose is 5 µ
Sv/h and 0.5 µSv/h in the remaining space, including the laboratory space as shown in
figure 6.13. The dose at the roof level is approximately 10 µSv/h and less at the visitor
platform level.
If 20% of the carbon beam is lost in SS20, the ambient dose equivalent at the interaction
point is 103 µSv/h and outside the shielding wall is 10 µSv/h. At the visitor platform
the dose is 50 µSv/h, and it is 70 µSv/h at the roof level. In the laboratory area, the
ambient dose equivalent is less than 10 µSv/h near the shielding walls and it decreases
with distance to 1 µSv/h as shown in figure 6.14.
In the worst case scenario, when the entire beam is lost in SS30, the dose at the inter-
action point is 104 µSv/h. At the visitor platform the dose is high, 500 µSv/h, while at
the roof level it is 103 µSv/h. In the same direction, but behind the shielding wall, the
dose is 102 µSv/h and in the laboratory the dose is 10 µSv/h as shown in figure 6.15.
The results indicate that, when 20% of the carbon ion beam is lost, the dose at the
visitor platform will not exceed 50 µSv/h. If 100% of the beam is lost in SS30, then
the dose at the visitor platform will be 500 µSv/h and in the research laboratory it will
be 10 µSv/h. As this dose has a high value and exceeds the legal limits at the visitor
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Figure 6.13: Ambient dose equivalent in SS10 for 12C at 1% beam loss.
Figure 6.14: Ambient dose equivalent in SS20 for 12C at 20% beam loss.
platform, a roof should be added on top of the machine in order to comply with the
CERN Safety Code [48].
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Figure 6.15: Ambient dose equivalent in SS30 for 12C at 100% beam loss.
Oxygen at 1%, 20%, 100% beam loss without roof
When a 250 MeV/n oxygen ion beam interacts with the injection line SS10, at the
interaction point, the dose will be 500 µSv/h for 1% beam loss. Outside the shielding
wall, near the interaction point, the ambient dose equivalent is 3 µSv/h. As suggested
by figure 6.16, at the target level, the secondary radiation will be attenuated by the
shielding walls, therefore the ambient dose equivalent outside the shielding walls is less
than 1 µSv/h. At the roof level, the dose is approximately 10 µSv/h and less at the
platform level.
When 20% of the oxygen beam is lost in SS20, the dose produced at the interaction of the
beam with the SS20 line is 103 µSv/h. Behind the shielding wall, near the interaction
point, the dose is 102 µSv/h and around 1 µSv/h in the laboratory. At the visitor
platform the dose is found to be 50 µSv/h as shown in figure 6.17.
If the entire beam is lost in SS30, the ambient dose equivalent at the interaction point
is 103 µSv/h and at the platform level (6.5 metres above the beam line) it is 500 µSv/h
above the interaction point and 700 µSv/h at the platform level. Behind the shielding
wall, the dose is 102 µSv/h near the shielding wall and it decreases with distance to 10
µSv/h as shown in figure 6.18.
The results obtained for oxygen showed that for 20% beam losses, the dose at the
platform level does not exceed 50 µSv/h, while in the laboratory space, the dose is 1
µSv/h. For 100% beam losses the dose is 500 µSv/h at the platform levels and higher
Radiation Protection Studies for Radiobiology 107
Figure 6.16: Ambient dose equivalent in SS10 for 16O at 1% beam loss.
Figure 6.17: Ambient dose equivalent in SS20 for 16O at 20% beam loss.
than 1 µSv/h in the lab space. These findings suggest that for beam losses higher than
20%, a roof should be added on top of the machine to protect the personnel and the
visitors, according to the safety regulations [48].
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Figure 6.18: Ambient dose equivalent in SS30 for 16O at 100% beam loss.
The second set of simulations was made with a concrete roof on top of the machine,
at 5 metres above the ground, in order to calculate the ambient dose equivalent at the
platform level for the worst case scenario to establish if the roof reduces the dose down to
the legal limits [48]. For simulations, the same parameters and the same geometry were
used. The thickness of the concrete roof is 80 cm. This is the thickness established by
the civil engineering department taking into account the existing walls of the accelerator
hall, but the final thickness of the shielding wall has to be decided when the beam loss
pattern in the LEIR machine can be estimated more precisely.
Hydrogen at 1%, 20%, 100% beam loss with roof
As shown in figure 6.19, with the roof on top of the machine, the dose inside the accel-
erator room is 1 µSv/h and at the interaction point is 102 µSv/h at the target level for
1% beam loss in SS10. Behind the shielding wall, in the direction of the beam line, the
dose equivalent is 10−2 µSv/h and it decreases with distance to 10−5 µSv/h. Because
of the roof, the radiation dose at the platform level is lower than 10−2 µSv/h.
As shown in figure 6.20, for 20% beam loss in SS20, the dose at the interaction point is
103 µSv/h and it decreases in the accelerator room to 1 µSv/h. At the visitor platform
the dose is found to be approximately 0.1 µSv/h. Behind the shielding wall, near the
interaction point, the dose is 1 µSv/h. In the laboratory, the roof reduces the dose to
10−4 µSv/h.
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Figure 6.19: Ambient dose equivalent in SS10 for H at 1% beam loss with roof.
Figure 6.20: Ambient dose equivalent in SS20 for H at 20% beam loss with roof.
At the interaction point, for 100% beam losses in SS30, the dose is 104 µSv/h. At the
visitor platform, the ambient dose equivalent is 1 µSv/h. In the accelerator room the
dose was found to be approximately 10 µSv/h. Outside the facility room, in the direction
of the interaction point, the ambient dose equivalent is 5 µSv/h and in the remaining
space goes down to 10−3 µSv/h as shown in figure 6.21.
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With a roof on top of the machine, the ambient dose equivalent at the platform level is
0.1 µSv/h at 20% beam losses, while the dose outside the shielding wall is 10−4 µSv/h.
At 100% beam losses, the ambient dose at the platform level is 1 µ Sv/h and 10−3
µSv/h in the laboratory. These values indicate that the concrete roof will attenuate the
radiation and the dose at the visitor platform will not exceed the CERN regulations
[48], therefore, the public can access the platform during the machine operation. The
dose inside the enclosed area is not increased considerable.
Figure 6.21: Ambient dose equivalent in SS30 for H at 100% beam loss with roof.
Helium at 1%, 20%, 100% beam loss with roof
For helium with 1% beam losses in SS10, the ambient dose equivalent at the target level
is 10 µSv/h at the interaction point and it decreases to 0.1 µSv/h in the remaining space.
At the visitor platform, the dose is only 10−2 µSv/h, as shown in figure 6.22, thanks to
the roof, compared with the value of 1 µSv/h without it. Outside the shielding walls,
near the interaction point, the dose is 10−3 µSv/h and 10−6 µSv/h in the remaining
space, including the laboratory space, as the roof was placed on top of the machine.
When 20% of the beam is lost in SS20, the ambient dose equivalent at the interaction
point is 102 µSv/h and it decreases gradually with distance to 1 µSv/h in the accelerator
room, while at the visitor platform the dose is 0.5 µSv/h. Behind the shielding wall, in
the direction of the interaction point, the ambient dose equivalent is 0.1 µSv/h and it
decreases to 10−5 µSv/h as shown in figure 6.23.
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Figure 6.22: Ambient dose equivalent in SS10 for He at 1% beam loss with roof.
Figure 6.23: Ambient dose equivalent in SS20 for He at 20% beam loss with roof.
In the improbable case of 100% beam losses in SS30, the ambient dose equivalent is 500
µSv/h at the interaction point and 10 µSv/h in the remainder space. At the visitor
platform, the dose is 0.8 µSv/h. Behind the shielding wall, where the interaction occurs
it is 0.1 µSv/h and it decreases with distance down to 10−4 µSv/h as shown in figure
6.24.
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When the roof is added, the results for a helium ion beam show that the dose at the
visitor platform and outside the shielding walls is low and no additional shielding is
required.
Figure 6.24: Ambient dose equivalent in SS30 for He at 100% beam loss with roof.
Carbon at 1%, 20%, 100% beam loss with roof
When a 250 MeV/n carbon beam hits SS10, the dose at the interaction point is 102
µSv/h for 1% beam loss and it decreases down to 1 µSv/h in the remaining space of
the accelerator room. Behind the shielding wall, the highest dose is found to be in the
direction of the beam line and it is 1 µSv/h. At a distance of a few metres, the ambient
dose equivalent is 0.01 as shown is figure 6.25. At the visitor platform, the dose goes
down to 0.1 µSv/h.
If 20% of the beam is lost in SS20, the dose at the interaction point is 103 µSv/h and
10 µSv/h in the remaining space. At the visitor platform it will be around 5 µSv/h.
Outside the shielding walls, the dose is 10 µSv/h in the proximity of the interaction
point and it decreases to 0.1 µSv/h further from that point as shown in figure 6.26.
Even for 100% beam loss IN SS30, the dose at the interaction point is 104 µSv/h and it
decreases to 102 µSv/h in the accelerator room. At the visitor platform, the dose will
be 10 µSv/h. After the shielding wall, the ambient dose equivalent is still high at 102
µSv/h and it decreases to 1 µSv/h as shown in figure 6.27.
After the roof was added on top of the machine, the dose at the visitor platform was
reduced, even for 100% beam losses, from 100 µSv/h to a safe value of 10 µSv/h.
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Figure 6.25: Ambient dose equivalent in SS10 for 12C at 1% beam loss with roof.
Figure 6.26: Ambient dose equivalent in SS20 for 12C at 20% beam loss with roof.
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Figure 6.27: Ambient dose equivalent in SS30 for 12C at 100% beam loss with roof.
Oxygen at 1%, 20%, 100% beam loss with roof
For a 250 MeV/n oxygen beam, the ambient dose equivalent at the interaction point is
102 µSv/h for 1% beam losses in SS10. The dose in the accelerator room will decrease
from 102 µSv/h to 1 µSv/h at the farthest point, while at the visitor platform, the dose
was found to be 5 µSv/h. Outside the shielding wall, near the incident point, the dose
is 0.1 µSv/h and near the research lab it decreases to 0.001 µSv/h as shown in figure
6.28.
When the beam losses goes up to 20% in SS20, the ambient dose at the interaction point
is 103 µSv/h and 10 µSv/h in the remaining space. At the visitor platform the dose will
increase to 7 µSv/h. Outside the shielding wall is 5 µSv/h near the interaction point
and it decreases with distance to 0.1 µSv/h as shown in figure 6.29.
In the worst case scenario, when the entire beam is lost in SS30, the dose at the in-
teraction point is high, 104 µSv/h, and inside the room it is 102 µSv/h. At the visitor
platform it was found to be approximately 50 µSv/h. In the laboratory, the dose is 10
µSv/h near the incident point but at the farthest point, the dose is 0.5 µSv/h as shown
in figure 6.30.
If the roof is placed on the top of th machine, the dose will be reduced to safe levels at
the visitor platform and in the research laboratory even at 100% beam losses. Therefore,
no additional mitigation methods need to be applied in this case as the concrete roof
provides a good shielding.
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Figure 6.28: Ambient dose equivalent in SS10 for 16O at 1% beam loss with roof.
Figure 6.29: Ambient dose equivalent in SS20 for 16O at 20% beam loss with roof.
Radiation Protection Studies for Radiobiology 116
Figure 6.30: Ambient dose equivalent in SS30 for 16O at 100% beam loss with roof.
6.4 Conclusion
The aim of this study was to evaluate the ambient dose equivalent rate for the new oper-
ation conditions of the LEIR synchrotron. The OpenMed/BioLeir project was proposed
as a use of the existing facility at CERN to provide beams for experiments in support
of research for hadron therapy centres. The first radiation protection calculations were
done only for Pb, Xe and Ar ions [120]. The purpose of this study was to evaluate the
ambient dose equivalent for hydrogen, helium, carbon and oxygen ions, as these types
of ions are of interest for treating cancer. The calculations were made for these different
ion beams for three scenarios, one representing the worst-case scenario (100% beam loss)
and the two additional ones corresponding to normal condition (1%, 20%) in different
locations and presented for tree different heights (1.7 m, 5 m, 6.5 m). LEIR is the only
accelerator at CERN provided with a visitor platform, hence, this study was done in
order to establish if the dose at the visitor platform and in the adjacent laboratory space
complies with the legal limits stipulated in the CERN Safety Code [48]. The first set of
simulations was done with the existing geometry of the facility, while the second set of
simulations was done with a concrete roof on top of the machine.
For the first set of simulations, the results showed that the dose at the interaction point
is quite significant. At the point on interest, at the platform level (6.5 m) the dose is
lower than at the roof level: less than 1 µSv/h for 1% beam loss in SS10, 5 µSv/h for
20% beam losses in SS20 and 60 µSv/h for 100% beam losses in SS30 for protons and
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helium ions, while for carbon and oxygen ions the dose is less than 10 µSv/h for 1%
beam losses, 50 µSv/h for 20% beam loss and 500 µSv/h for 100% beam loss.
Behind the shielding walls, the dose for carbon and oxygen is 0.5 µSv/h at 1% beam
loss, 1 µSv/h at 20% beam loss and 10 µSv/h at 100% beam loss. For hydrogen and
helium it is 0.01 µSv/h at 1% beam loss, 0.5 µSv/h at 20% beam loss and higher than
1 µSv/h at 100% beam loss as shown in figure 6.31.
These results suggest that for normal conditions when only 1% up to 20% of the beam
will be lost, the ambient dose equivalent at the visitor platform and in the research
laboratory is below the CERN limits [48] which are based on the IRR99 [40] limits. In
case of an accident, when the entire beam will be lost, the dose at the visitor platform
will exceed the legal limit and a concrete roof on top of the synchrotron will help in
reducing the dose at this level and also in the research laboratory.
As a consequence, if no roof will be placed on top of the machine, the human intervention
(staff and visitors) in the vicinity of the machine has to be kept at minimum as the dose
exceeds the limits [48] and the facility room has to be classified as limited stay radiation
area [48]. Before access is provided to the irradiation room, the ventilation system has
to be flushed and after the flushing has to be verified by the access system. Only after
this verification, can access to the irradiation room be granted.
Figure 6.31: Ambient dose equivalent at the platform level for 12C at 20% beam loss
without roof.
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For the second set of simulations, a concrete roof of 80 cm thickness was added at 5
metres height.
The results showed that at the interaction point and in the accelerator room, the ambient
dose equivalent has the same value as the dose calculated in the first set of simulations.
However, behind the shielding walls, the ambient dose equivalent is really low for all
ions, even 10−5 µSv/h a few metres away from the shielding walls, except for the wall
side where the interaction occurs.
At the visitor platform level, on top of the roof, the radiation level for protons and
helium is 10−2 µSv/h for 1% beam losses, 0.1 µSv/h at 20% beam losses and 1 µSv/h
for 100% beam losses, while for carbon and oxygen it is 0.1 µSv/h for 1% beam losses,
5 µSv/h for 20% beam losses and below 10 µSv/h for 100% beam losses. These results
indicate that, even for 100% beam losses, the roof will attenuate the dose at the visitor
platform and the dose will not reach the legal limit of 10 µSv/h [48] as seen in figure
6.32.
Figure 6.32: Ambient dose equivalent at the platform level for 12C at 20% beam loss
with roof.
All these results indicate that for an energy of 250 MeV/n, in the present conditions
without the concrete roof on top of the machine, the dose at the platform level will not
exceed the CERN regulations [48] for normal beam losses (1%, 20%).
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Particle 1% 20% 100%
without/with roof without/with roof without/with roof
Hydrogen 1 µSv/h / 10−2 µSv/h 5 µSv/h / 0.1 µSv/h 60 µSv/h / 1 µSv/h
Helium 1 µSv/h / 10−2 µSv/h 5 µSv/h / 0.1 µSv/h 60 µSv/h / 1 µSv/h
Carbon 10 µSv/h / 0.1 µSv/h 50 µSv/h / 5 µSv/h 500 µSv/h / 10 µSv/h
Oxygen 10 µSv/h / 0.1 µSv/h 50 µSv/h / 5 µSv/h 500 µSv/h / 10 µSv/h
Table 6.2: Ambient dose equivalent at the visitor platform level.
If the beam losses will be higher than 20%, an additional roof should be placed on top
of the machine as the dose limit is exceed and the room has to be classified as limited
stay radiation area [48] The same argument may be used in case of the ambient dose
equivalent found in the research laboratory. In normal condition, the 3 µSv/h will not
be exceeded, but in case that the beam losses will reach 100%, the dose limit will be
exceeded. All the results are summarized in table 6.2. As the future plans is to upgrade
the machine to be able to deliver ion beams with an energy of 430 MeV/n, from the
radiation protection point of view, a concrete roof should be placed on top of the machine
to minimize the secondary radiation and, therefore, the radiation exposure of visitors
and personnel.
Unfortunately, the BIOLEIR project is not going further but if the programme is revived
these calculations will be used as primary information for the conceptual design phase.
Chapter 7
Conclusion and future work
Hadron therapy is a complicated technique and the effectiveness of the treatment de-
pends on several factors arising from physical and biological properties of the processes
involved and practical constraints of the treatment itself.
An important aspect in hadron therapy is the secondary radiation produced during the
treatment. The secondary particles, like neutrons, can have an impact on the total dose
received by the patient in the healthy tissues. The main concern is that a small dose of
this secondary radiation can induce a secondary cancer as neutrons have a high RBE.
For this work, FLUKA Monte Carlo simulations were performed, using beam line pa-
rameters of the Clatterbridge Cancer Centre, the Christie Proton Therapy Centre and
the OpenMed facility, to establish if the radiation protection regulations are fulfilled.
7.1 The Clatterbridge Cancer Centre
The aim of this project was to calculate the proton depth-dose distribution, the proton
and neutron fluence and dose along the beam line, the neutron dose equivalent in a
water phantom and the radioactivity induced in a patient-specific collimator and in the
treatment room.
The FLUKA Monte Carlo simulations were used to calculate the Bragg peak for a 60
MeV proton beam. The results showed that the highest dose is delivered at 3 cm depth.
This value agrees with the experimental value obtained in Ref. [98].
The proton fluence and the proton dose were also calculated to verify if the quality of
the proton beam is not altered along the path. The FLUKA simulations showed that
most of the secondary particles are produced in the modulating devices and in the brass
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collimator but the fluence and the dose are low, therefore, the components will not alter
the proton beam.
The next simulations were made to determine the neutron secondary dose. Generally,
the contribution of the secondary particles to the total dose received by the healthy
tissue is low. The dose also depends on the material and the geometry of the beam line.
For a 60 MeV proton beam, the contribution of the neutrons to the total dose received
by the patient is insignificant. The neutron dose equivalent ranged between 50 µ Sv/s
and 70 µ Sv/s in the target volume and between 1 µ Sv/s and 20 µ Sv/s outside the
target volume. These findings indicate that the secondary neutron dose is relatively
low and below the UK limitations.[40] Therefore the precise target conformity of proton
therapy is not affected. The FLUKA simulations have been verified with the MCNPX
code and the results showed a good agreement, but it will be important to validate the
simulations with experimental data as these are the first and the only radiation protec-
tion calculations made at the Clatterbridge Cancer Centre. As no experimental data
was available at the time, the Monte Carlo results were compared with the experimen-
tal data conducted at a similar facility at CCB IFJ PAN in Krakow.[103]. The results
obtained were 0.8 µ Sv/s at the patient chair which is good agreement with 1 µ Sv/s
found by the FLUKA Monte Carlo Code. These values suggest that the secondary dose
received by the patient do not exceed the legal limits of IRR99.[40]
The next simulations involved the study of radioactivity induced in the brass collimator
and in the treatment room. The calculations were made for five decay times.
For the brass collimator, the results showed that some radioisotopes like 60Ga, 64Cu,
63Zn, 61Cu and 58Co have a high activity even after 1 hour from irradiation, but the
values do not exceed the limits recommended in the IRR99 [40]. Nevertheless, even
though the results showed that the collimator is not radioactive, the contact with the
contaminated collimator should be avoided for at least one hour to minimize the exposure
of the personnel to radiations.
The radioactivity was calculated also in the treatment room. The results suggest that
the activity found in the air is low, hence the personnel are not significantly exposed to
additional radiation.
However, these results can not be applied in every case as they depend on the duration
of each irradiation profile and on the air ventilation scheme in the treatment room.
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7.2 The Christie Proton Therapy Centre
The Christie Proton Therapy Centre is planned to treat the first patient in 2018. The
facility will have three treatment rooms and one research room.
The objective of this research was to undertake radiation protection studies for the
research room and the accessible areas around it. The ambient dose equivalent for neu-
trons and high energy photons was calculated for proton beams with different energies:
70 MeV, 100 MeV, 150 MeV, 200 MeV and 250 MeV. The production of radioactive
isotopes was also investigated.
The results suggest that the secondary dose increases linearly with energy, especially in
the direction of the beam line. For 70 MeV, the neutron and the photon dose in the
accessible areas was found to be 1 µ Sv/h and 0.1 µ Sv/h respectively. Therefore, for
a 70 MeV proton beam, the dose can be regarded as safe for employees and members
of public.[40]. In the worst-case scenario when the entire beam is lost at maximum
energy, the ambient dose equivalent will not exceed 10 µ Sv/h in the areas adjacent to
the research room, while in the research room, the dose will be high, around the beam
line the neutron ambient dose equivalent was found to be 6 mSv/h. These values can
be regarded safe if we refer to employees over 18 years, but not for members of public
or pregnant employees as the limit imposed by the IRR99[40] is 1 mSv in a calendar
year. Therefore, the access of the members of public, in the adjacent areas, should be
limited when the beam is on to comply with the legal requirements.[40] The results of
the dose rate obtained with FLUKA were compared with the MCNPX results presented
in Ref.[113]. The comparison showed that the values are quite similar. In the maze, the
dose equivalent calculated with FLUKA is with 1 mSv higher than the dose equivalent
calculated with MCNPX, while on the corridor, the dose equivalent has approximately
the same value for both codes. The dose in the treatment room was found to be 100
times higher with FLUKA. These difference could appear due to the detectors position
or due to the different physics properties enabled in the input files used for MCNPX and
FLUKA codes. To resolve these discrepancies, an additional set of simulations should
be done with a more detailed geometry.
For the second set of simulations, the radioactivity induced in the room together with
the residual dose rate was studied. The irradiation profile was set for 1.4 hours per day
of activity at full intensity (109 protons/s). Immediately after irradiation at 70 MeV
the most abundant isotopes are 15O, 13N and 11C, while at 150 MeV it was found that
the activity of 41Ar increased, simultaneously with the activity of 15O, 13N and 11C. At
250 MeV, the activity of 11C increases considerably up to the IRR99 limit.[40]. For 15O,
13N and 11C, the activity induced in the research room air is below the limits given in
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IRR99.[40] If the accelerator is operated at maximum energy, only 11C will exceed the
limit. These results demonstrate that the research room has a low risk of contamination
and the personnel will not be exposed, as the activity of the most important radioisotopes
is below the limits given in the IRR99.[40]. It should be noted that these results have
been studied for the worst-case scenario, where the accelerator is operated at maximum
beam energy (250 MeV) for a period of 1 year. In addition, the irradiation profile was
only presumed and the results will differ depending on the scenario. To obtain more
realistic results, it will be necessary to develop more irradiation scenarios, as detailed
and complete as possible.
The residual dose induced in the research room was also calculated. The results showed
that, immediately after irradiation, the residual dose equivalent in the research room is
of the order of several µSv/h: 1 µSv/h for 70 MeV and > 100 µSv/h for 250 MeV.
After 1 hour, the value of the dose decreases significantly down to 50 µSv/h for 250
MeV. After 3 months, the dose decays down to 10−3 µSv/h. The results suggest that
at 250 MeV the human intervention in the research room should be kept as minimum
possible after irradiation, but after 1 hour of cooling time, it can be seen as safe.
7.3 The OpenMed facility
The OpenMed project involved radiation protection calculations for the new planned
facility at CERN. The plans are to use an existing facility for radiological studies. The
first radiation protection simulations were made for the present conditions: Pb, Xe and
Ar ions. After the machine is upgraded, it will accelerate different ion beam used in
pre-clinical radiation biology: hydrogen, helium, carbon and oxygen.
The main interest of this project was to decide if under the new conditions, the existing
shielding will protect the workers and visitor, as the LEIR synchrotron is the only
accelerator at CERN provided with a visitor platform. Therefore, the ambient dose
equivalent was calculated for four different types of ion beams at different room heights
in order to see if a roof needs to be placed on top of the synchrotron and to ensure that
the shielding provided is safe enough for workers and visitors and that the ambient dose
equivalent is within the legal limits applied at CERN.[48]
For the first set of simulations, with no roof on top of the machine, the results showed
that the dose at the point of interest, at the platform level (6.5 m), is less than 1 µSv/h
for 1% beam loss, 5 µSv/h for 20% beam losses and 60 µSv/h for 100% beam losses
for protons and helium ions, while for carbon and oxygen ions the dose is less than 10
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µSv/h for 1% beam losses, 50 µSv/h for 20% beam loss and 500 µSv/h for 100% beam
loss.
Outside the shielding walls, the dose for carbon and oxygen is 0.5 µSv/h at 1% beam
loss, 1 µSv/h at 20% beam loss and 10 µSv/h at 100% beam loss. For hydrogen and
helium is 0.01 µSv/h at 1% beam loss, 0.5 µSv/h at 20% beam loss and higher than 1
µSv/h at 100% beam loss.
These results suggest that for normal conditions when 1% up to 20% of the beam will be
lost, the ambient dose equivalent at the visitor platform and in the research laboratory
is below the CERN limits [48] which are compatible with the IRR99[40] limits. If the
entire beam is lost, the dose at the visitor platform will exceed the legal limit and a
concrete roof on top of the synchrotron will help in reducing the dose at this level and
also in the research laboratory.
As a consequence, if no roof will be placed on top of the machine, the human intervention
(staff and visitors) in the vicinity of the machine has to be kept at minimum.
If a 80 cm thickness concrete roof will be placed on top of the machine, the dose at the
platform level will be reduced by a factor of 100, even in case of 100% beam losses. This
is a strong argument that the roof should be placed on top of the machine, especially
if the machine is planned to be upgraded to deliver ion beams with an energy of 430
MeV/n/
Overall, in this work, Monte Carlo simulations, of practical cases from operational
hadron therapy centres, have been presented in order to improve the quality and the
precision of hadron therapy treatment procedures from radiation protection point of
view.
Even though some of the results obtained in this thesis with FLUKA Monte Carlo
code were verified with a different Monte Carlo code like MCNPX, the results can not
represent a standard. There are limitations, like to recreate an exact irradiation profile,
due to missing details. Therefore, all these results should be compared with experimental
data.
Some of the simulations represent the first calculation of the secondary ambient dose
equivalent at these facilities. Therefore, I strongly believe that this work is extremely
useful as it will be used to improve the irradiation conditions, hence to protect the
patients and the personnel from possible radiation exposure.
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Appendix
This is the FLUKA input file used for radiation protection studies for the Christie
Proton Therapy Centre (simulation with a beam energy of 250 MeV). File for the other
simulations are similar apart form the geometry.
* Set the defaults for precision simulations
DEFAULTS
PRECISIO
* Define the beam characteristics
BEAM -0.25 1.0 1.0 PROTON
* Define the beam position
BEAMPOS 150.0 550.0 1570.
NEGATIVE
PHYSICS 3. EVAPORAT
PHYSICS 3. COALESCE
PHYSICS 2. EM-DISSO
IONTRANS HEAVYION
EMFCUT -0.0001 1E-4 VACUUM @LASTMAT
PROD-CUT
GEOBEGIN
COMBNAME
0 0
* Black body
SPH blkbody 0.0 0.0 0.0 100000.0
* Void sphere
SPH void 0.0 0.0 0.0 10000.0
RPP body1 0.0 300.0 1000.0 1300.0 -321.01 1557.18
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RPP body2 0.0 300.0 -200.0 0.0 -156.29 1357.18
RPP body3 0.0 300.0 1000.0 1150.0 -663.54 -321.01
RPP body4 0.0 300.0 1000.0 1060.0 -666.15 -663.54
RPP body5 0.0 300.0 516.0 1000.0 -663.54 -513.54
RPP body6 0.0 300.0 456.0 516.0 -666.29 -513.54
RPP body7 0.0 300.0 0.0 746.5 -156.29 -31.29
RPP body8 0.0 300.0 -200.0 -50.0 -663.54 -156.29
RPP body9 0.0 300.0 -110.0 -50.0 -666.29 -663.54
RPP body10 0.0 300.0 -50.0 746.5 -281.09 -156.29
RPP body11 0.0 300.0 250.0 300.0 -666.29 -281.09
RPP body12 0.0 300.0 746.5 807.5 -281.09 29.91
RPP body13 0.0 300.0 -685.0 -200.0 -663.54 -513.54
RPP body14 0.0 300.0 250.0 900.0 1600.0 1765.0
SPH body16 0.0 746.5 -156.29 5108.8159097779
XYP Zmin 600.0
BOX body17 0.0 390.0 1690.0 0.0 -510. -470. 0.0 -105.4224251945 114.39454648764
1000.0 0.0 0.0
BOX body15 0.0 1000.0 1400.0 0.0 -230. 360. 0.0 94.216306066234 60.19375109788
1000.0 0.0 0.0
XZP CutY -200.0
XYP CutZ 1765.0
ZCC BTOut 150.0 550.0 5.0
ZCC BTIn 150.0 550.0 4.8
XYP Zmax 1550.0
RPP Phantom 145.0 155.0 545.0 555.0 565.0 605.0
RPP floor -2.0 0.0 0.0 1000.0 0.0 1550.0
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END
* Black hole
BLKBODY 5 +blkbody -void
* Void around
VOID 5 +void +void -body1 -body2 -body3 -body4 -body5 -body6 -body7 -body8 -
body9 -body10 -body11 -body12 -body13 -body14 -body16
Wall1 5 +body1 -body15
Wall2 5 +body2 -body17-CutY
Wall3 5 +body3
Wall4 5 +body4
Wall5 5 +body5
Wall6 5 +body6
Wall7 5 +body7
Wall8 5 +body8
Wall9 5 +body9
Wall10 5 +body10
Wall11 5 +body11
Wall12 5 +body12
Wall13 5 +body13
Wall14 5 +body14 -body15 -(body17+CutZ )
Air 5 +body16 -body1 -body2 -body10 -body11 -body12 -body13 -body14 -body3 -
body4 -body5 -body6 -body7 -body8 -body9 -(body15 +CutZ) -(body17 -CutY +CutZ)
-Phantom -(+BTOut -BTIn +Zmax -Zmin)-floor
BLOCK1 5 +body17 -CutY +CutZ
BLOCK2 5 +body15 +CutZ
BeamTube 5 +BTOut -BTIn +Zmax -Zmin
BeamVac 5 +BTIn +Zmax -Zmin
Radiation Protection Studies for Radiobiology 128
PHANTOM 5 +Phantom
FLOOR 5 +floor
END
GEOEND
* Concrete * Concrete has a wide variation in density and composition. The above *
description is for poured structural concrete with 10% moisture * content. Concrete
block will have a density of about 2.05 g/cm3. * Ranges of concrete composition are :
C (8-25%), O (38-60%), Si (8-18%). * Concrete composition can be analysed cheaply
by commercial laboratories.
MATERIAL 2.34
Concrete
COMPOUND 23.0 CARBON 40.0 OXYGEN 12.0
SILICON Concrete
COMPOUND 12.0 CALCIUM 10.0 HYDROGEN 2.0 MAGNESIU Concrete
LOW-MAT Graphite 6. -3. 296. CARBON
MATERIAL 6. 2.26
Graphite
MATERIAL 24. 7.18
CHROMIUM
MATERIAL 25. 7.21
MANGANES
MATERIAL 15. 1.82 PHOSPHO
MATERIAL 16. 2.07 SULFUR
* Steel316LN
* Stainless steel AISI316LN
MATERIAL 7.8 SS316LN
COMPOUND -.67145 IRON -0.185 CHROMIUM -0.1125 NICKELSS316LN
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COMPOUND -0.02 MANGANES -0.01 SILICON -4.5E-4 PHOSPHOSS316LN
COMPOUND -3.E-4 SULFUR -3.E-4 CARBON SS316LN * ..+....1....+....2....+....3....+....4....+....5....+....6....+....7..
ASSIGNMA BLCKHOLE BLKBODY
ASSIGNMA VACUUM VOID
ASSIGNMA Concrete Wall1
ASSIGNMA Concrete Wall2
ASSIGNMA Concrete Wall3
ASSIGNMA Concrete Wall4
ASSIGNMA Concrete Wall5
ASSIGNMA Concrete Wall6
ASSIGNMA Concrete Wall7
ASSIGNMA Concrete Wall8
ASSIGNMA Concrete Wall9
ASSIGNMA Concrete Wall10
ASSIGNMA Concrete Wall11
ASSIGNMA Concrete Wall12
ASSIGNMA Concrete Wall13
ASSIGNMA Concrete Wall14
ASSIGNMA AIR air
ASSIGNMA Concrete BLOCK1
ASSIGNMA Concrete BLOCK2
ASSIGNMA ALUMINUM BeamTube
ASSIGNMA VACUUM BeamVac
ASSIGNMA WATER PHANTOM
ASSIGNMA SS316LN FLOOR
* irradiation profile
Radiation Protection Studies for Radiobiology 130
* ——— RADDECAY 1. 3.0 99999
* 1.4h irradiation
IRRPROFI 5040.0 1.E9 82800. 0.0 5040.0 1.E9
IRRPROFI 82800. 0.0 5040.0 1E9 82800.0 1E9
* 1.4h irradiation
IRRPROFI 5040.0 1.E9 82800. 0.0 5040.0 1.E9
IRRPROFI 82800. 0.0 5040.0 1E9 82800.0 1E9
* cooling times: 0min 1 hour 1 day 1 month 3 months 1 year
DCYTIMES 0.0 3600.0 86400.0 2592000.0 7776000.0 31104000.
* Floor activation
DCYSCORE 1. FlAct-0s
RESNUCLE
RESNUCLE 3. -21. FLOOR
FlAct-0s
DCYSCORE 2. FlAct-1h
RESNUCLE
RESNUCLE 3. -22. FLOOR
FlAct-1h
DCYSCORE 3. FlAct-1d
RESNUCLE
RESNUCLE 3. -23. FLOOR
FlAct-1d
DCYSCORE 4. FlAct-1m
RESNUCLE
RESNUCLE 3. -24. FLOOR
FlAct-1m
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DCYSCORE 5. FlAct-3m
RESNUCLE
RESNUCLE 3. -25.
FlAct-3m
DCYSCORE 6. FlAct-1y
RESNUCLE
RESNUCLE 3. -26.
FlAct-1y
* Air activation
DCYSCORE 1. Air-0s
RESNUCLE
RESNUCLE 3. -27. air Air-0s
DCYSCORE 2. Air-1h
RESNUCLE
RESNUCLE 3. -28. air Air-1h
DCYSCORE 3. Air-1d
RESNUCLE
RESNUCLE 3. -29. air Air-1d
DCYSCORE 4. Air-1m
RESNUCLE
RESNUCLE 3. -30. air Air-1m
DCYSCORE 5. Air-3m
RESNUCLE
RESNUCLE 3. -31. air Air-3m
DCYSCORE 6. Air-1y
RESNUCLE
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RESNUCLE 3. -32. air Air-1y
* Neutron prompt dose eq
USRBIN 10. DOSE-EQ -33. 500.0 2000.0 2000.0 DoseeqN
USRBIN -2.0 -1000.0 -1000.0 100.0 100.0 100.0
AUXSCORE USRBIN NEUTRON DoseeqN AMB74
* Photon prompt dose eq
USRBIN 10. DOSE-EQ -34. 500.0 2000.0
2000.0DoseeqPh
USRBIN -2.0 -1000.0 -1000.0 100.0 100.0 100.0
AUXSCORE USRBIN PHOTON DoseeqPh AMB74
* Residual Dose equivalent rate
*
DCYSCORE 1. Doseeq0s USRBIN
AUXSCORE USRBIN Doseeq0s AMB74
USRBIN 10. DOSE-EQ -35. 500.0 2000.0 2000.0Doseeq0s
USRBIN -2.0 -1000.0 -1000.0 100.0 100.0 100.0
DCYSCORE 2. Doseeq1h USRBIN
AUXSCORE USRBIN Doseeq1h AMB74
USRBIN 10. DOSE-EQ -36. 500.0 2000.0 2000.0Doseeq1h
USRBIN -2.0 -1000.0 -1000.0 100.0 100.0 100.0
DCYSCORE 3. DoseEq1d USRBIN
AUXSCORE USRBIN DoseEq1d AMB74
USRBIN 10. DOSE-EQ -37. 500.0 2000.0 2000.0DoseEq1d
USRBIN -2.0 -1000.0 -1000.0 100.0 100.0 100.0
DCYSCORE 4. Doseeq1m USRBIN
AUXSCORE USRBIN Doseeq1m AMB74
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USRBIN 10. DOSE-EQ -38. 500.0 2000.0 2000.0Doseeq1m
USRBIN -2.0 -1000.0 -1000.0 100.0 100.0 100.0
DCYSCORE 5. Doseeq3m USRBIN
AUXSCORE USRBIN Doseeq3m AMB74
USRBIN 10. DOSE-EQ -39. 500.0 2000.0 2000.0Doseeq3m
USRBIN -2.0 -1000.0 -1000.0 100.0 100.0 100.0
DCYSCORE 6. Doseeq1y USRBIN
AUXSCORE USRBIN Doseeq1y AMB74
USRBIN 10. DOSE-EQ -40. 500.0 2000.0 2000.0Doseeq1y
USRBIN -2.0 -1000.0 -1000.0 100.0 100.0 100.0
* Set the random number seed
RANDOMIZ 1.0
* Set the number of primary histories to be simulated in the run
START 1000000.0
STOP
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